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Chapter 1
Introduction
The efficacy of the endocrine system relies on the specific interaction of a hormone
to its receptor. In case of peptide hormones and cytokines, this involves complex
interactions between proteins and multiple molecular recognition events. One of the
best studied examples of these interactions is between growth hormone (GH) and
its receptor (GHR). Understanding of the signaling mechanisms triggered by the
binding of GH to GHR has rapidly advanced in the past several years. Several fac-
tors like stress, sleep, and exercise can enhance GH  secretion in the blood, which
then will bind cell-surface receptors (GHRs) on target tissues such as liver, muscle,
adipose, and bone. This activates tightly regulated signaling cascades that will trig-
ger several of the GH responses and promotes, at the same time, the GHR down-
regulation. The ubiquitin-proteasome system plays also an important role in the
GHR downregulation. GH or GHR defects, like mutations or deletions can have
important effects in GHR's signal transduction or downregulation, which can lead
to severe deficiencies and syndromes. GH has long been used to treat children with
short stature and may increase protein synthesis and prevent muscle wasting in
patients with burns or AIDS. The GHR and it hormone are of basic importance for
regulation of metabolism in man, and therefore its cell biology must be carefully
and precisely regulated.  
The cytokine/hematopoietin receptor superfamily 
The GHR is a single-transmembrane polypeptide that belongs to the class I of the
cytokine receptor superfamily (1). All members of this family, which include recep-
tors for prolactin (PRL), erythropoietin (Epo), thrombopoietin, leptin, ciliary neu-
rotropic factor (CNTF) leukemia inhibitory factor (LIF), granulocyte-colony sti-
mulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-
CSF), and several interleukins, share homologous structural motifs (2, 3). Receptors
for interferon (IFN) α/β, IFNγ, and IL-10 are more distantly related and considered
class II receptors in the family (4). The class I cytokine receptors span the mem-
brane once and contain an extracellular region, a single hydrophobic transmem-
brane domain of 24 amino acids, and an intracellular region. In their extracellular
ligand binding domain, four conserved cysteine residues are found in the amino-ter-
minal part and a conserved WSXWS (Trp-Ser-X-Trp-Ser) motif is present in the C-
terminal part, predicted to function as a ligand interaction site (5). In the GHR, this
motif is altered in amino acids Tyr-Gly-Glu-Phe-Ser (YGEFS). It does not contact
ligand, but upon a mutation of the last serine, both binding affinity and trafficking
of the receptor are impaired (6). Because it does not make direct contact with li-
gand, the YGEFS motif is likely to serve a structural role critical for ligand binding
(7). In the intracellular domains of cytokine receptors, no consensus catalytic site
was identified, and limited amino acid homology was only recognized in two
motifs: Box-1 and Box-2, located in the cytoplasmic membrane-proximal region of
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several members of the cytokine family (8), and known to be involved in signal
transduction (8, 9). Box-1, a proline-rich motif present in all members, consists of
a Pro-Xaa-Pro sequence and a preceding cluster of hydrophobic amino acids.
Another motif, Box-2, is present in most of these receptors and is only 50% con-
served in the members of the receptor family. It is characterized as a cluster of
hydrophobic amino acids, is followed by negatively charged residues, and ends with
one or two basic amino acids. Another notable feature of this family of receptors is
their multi-component nature. This suggests that some receptors could share com-
ponents, providing a potential explanation for some of the remarkable functional
redundancy observed among several cytokines.
The Growth Hormone Receptor (GHR) structure
Physically, GHR is characterized by a Mr of ~ 130,000 (10). Based on amino acid
sequence, the calculated molecular mass of the GHR is 70 kDa, but posttransla-
tional modifications such as glycosylation and ubiquitination are responsible for the
higher molecular mass experimentally observed. The GHR was initially cloned
from rabbit and human cDNA libraries and subsequently from other species, pre-
senting amino acid sequence homologies of ~70% between the different species
(11). The rabbit GHR contains a total of 620 amino acid residues, of which 246 are
part of the extracellular domain, 24 of the transmembrane domain, and 350 of the
intracellular domain. The GHR extracellular domain consists of two domains
(amino acids 1-123 and amino acids 128-238) that are linked by four residues
(amino acids 124-127) (7). Each domain contains seven β strands arranged to form
a sandwich of two antiparallel β sheets. The N-terminal domain contains six cys-
teines that form three disulfide bonds between Cys 38-48, Cys 83-94, and Cys 108-
122 and one free cysteine (7, 12). The first of these disulfide bonds is essential for
ligand binding (13). Hydrogen bonds between Arg 43 and Glu 169, and a salt bridge
between Arg 39 and Asp 123 further stabilize the GHR (14). Five potential N-linked
glycosylation sites are conserved in the extracellular domain of the GHR in species
sequenced to date, several of which are glycosylated (15). The presence of alterna-
tively spliced mRNAs potentially encoding for short forms of the GHR has been
reported (16, 17). Such putative forms, which have not yet been demonstrated to be
readily translated in vivo, seem to be degraded more easily than the long form of
the receptor. In addition to the membrane-bound form of GHR, a soluble circulat-
ing form of the receptor, named growth hormone binding protein (GHBP), has been
characterized. GHBP is identical to the extracellular domain of the GHR and
depending on the species, different mechanisms are used to generate GHBP. In rat
and mouse, GHBP is encoded by a specific mRNA originated from alternatively
splicing, and contains a short hydrophylic C-terminal extension that is not found in
the membrane receptor (18, 19). Normally, the GHBP is generated by proteolytic
cleavage at the cell-surface, a process also known as shedding, of the membrane-
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bound form of the receptor by a recently identified metalloprotease called tumor
necrosis factor (TNF)-α-converting enzyme (TACE or ADAM-17) (20). Diverse
biological functions have been attributed to the GHBP. In plasma, complex forma-
tion of GHBP-GH creates a circulating GH reservoir, protects GH from degradation
and excretion, prolongs its half-life, and may enhance its bioactivity in vivo through
these mechanisms (21, 22). In tissues, GHBP acts in a dominant negative manner
by competing with GHRs for ligand and by forming unproductive GHR-GHBP he-
terodimers that are unable to signal (23). Direct and indirect evidence, particulary
in the liver, have suggested the GHBP as an useful tool of measuring GHR abun-
dance at plasma levels (24).
Possible GHR isoforms described above could be responsible for generation of a
large amount of GHBP. Such isoforms may act as a dominant negative to the long
form of GHR, suggesting that their expression could then modulate signaling by the
full-length receptor. Abnormal expression of one of these short forms, as well as
mutations in the GHR (deletion, frameshift, nonsense mutation or amino acid subs-
titution) have been shown in patients with Laron sindrome.
GH
Growth hormone (GH), also termed somatotropin or somatotrope hormone, is a
polypeptide hormone essentially secreted by the pituitary gland that exerts its
effects via cell-surface specific receptors located at the surface of target issues (25).
GH has long been known to mainly promote postnatal longitudinal body growth
and differentiation of muscle, bone, and cartilage cells, including organ size and
longitudinal bone growth (26). 
Through the interaction with the GHR, GH regulates the lipid, carbohydrate, nitro-
gen and mineral metabolism within a cell (27, 28). For example, recombinant
porcine GH administered to pigs and human GH administered to older men increa-
ses lean body mass and decreases fat (29, 30). 
GH induces two opposite actions on carbohydrate metabolism. First, the insulin-
like effect which last approximately 2 hours and involves lipogenesis and enhanced
glucose and amino acid metabolism (27). Glucose is taken into the cell and stored
as glycogen. Second, the anti-insulin effect which occurs much later (after 3 hours)
and includes lipolysis (production of free fatty acids), hyperglycemia, and hyperin-
sulinemia. The anabolic effects of GH lead to an increase in protein synthesis ulti-
mately resulting in an increase in lean muscle mass (31). GH plays an integral role
in the maintenance of the immune system. It is important for lymphocyte function
and required for a critical period of fetal bovine immune system development (32).
Through direct actions on the brain, GH may also modulate emotion, stress
response, and behaviour (33). 
Many of the actions of GH are mediated by the activation of insulin-like growth fac-
tor one (IGF-1). GH causes differentiation of precursor cells and also can stimulate
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IGF-1 secretion. The secreted IGF-1 exhibits a mitogenic effect on the differentia-
ted cells to cause clonal expansion of cell numbers. IGF-1 is produced by the liver,
bone and other types of tissues in response to GH and acts in a paracrine and
endocrine fashion (27). There is growing evidence that GH and IGF-1 are involved
in heart development and hypertrophy (34). Recombinant human GH (rGH) was
shown to increase myocardial mass and improve myocardial energy metabolism
and hemodynamics (34).
Hypersecretion of the hormone can lead to giantism and acromegaly in adults (35).
This condition causes enlarged bones, especially in the face, as well as oversized
organs. Alternatively hyposecretion of GH can lead to dwarfism. Body-fat reduc-
tion, one of the GH-induced actions, is clinically important in replacement therapy
for adult GH deficient patients with obesity. Although this action can be attributed
to hydrolysis of stored triglycerides by activation of hormone-sensitive lipase
(HSL), details on the molecular mechanism of GH-induced lipolysis stimulation are
still poorly understood (36). The major physiological component of pituitary gland
secreted GH (about 75%) is a single chain polypeptide of 191 amino acids and a
molecular mass of 22 kDa. At least four other monomeric GH isoforms, with molec-
ular masses 27, 20, 17 and 5 kDa, have been detected in the circulation to date, and
it has been reported that they might be partly responsible for short stature and
growth retardation in children (37). These non-22-kDa isoforms may be weak ago-
nists or even antagonists of the GHR binding, resulting in altered receptor homod-
imerization and activation depending on the relative affinities for binding sites 1
and 2 (see below) to the GHR (38).
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Figure 1. Squematic representation of the GHR. 
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Regulation of GHR expression
Development (ontogeny), hormonal presence, nutritional status, and tissue/cell spe-
cific control taken place at the transcriptional or translational level, regulate GHR
gene expression. Chronic GH treatment increases GH binding in hepatic tissues of
pig, rat and sheep (39, 40). GH upregulates the number of GH binding sites at the
cell-surface but, at the same time, initiates GHR downregulation (41, 42, 43). 
Mal-nutrition and fasting lead to a state of GH resistance characterized by increased
circulating levels of GH and decreased IGF-1 concentrations in mammals (44).
These hormonal changes are accompanied by a decrease in GHRs in hepatic mem-
branes (45). Glucose starvation results in a significant reduction (up to 45%) of the
expression of GHR in the presence of GH. Removal of arginine, proline, trypto-
phan, or valine resulted in only slight decreases in GHR mRNA. Energy, in the form
of glucose, appears to control GHR expression (46). 
Signaling Mechanisms of the GHR
GH-GHR2 dimer
Studies on the crystallographic structure of GH-GHR complexes revealed a trime-
ric complex of two receptors and a single molecule of hormone (7). Analysis of the
complex revealed two binding sites on hGH on opposite sides with slightly diffe-
rent binding affinities (47). The ligand binding domain and dimerization interface
at the extracellular part of the GHR lie on its cystein pairs and YGEFS motif. The
GH binding to the two receptors is considered the first step in the action of GH. This
process is initiated with GH binding to one molecule of receptor through its site 1,
a functional epitope of 11 amino acids, followed by association of this complex to
a second receptor molecule through GH's site 2, a 31 amino acid region that stabi-
lizes and, together with a ~500 Å contact region between the two extracellular
domains of GHR, defines the binding of the second GHR (reviewed in: 14). The
stoichiometry of a single GH binding two GHRs and the fact that site 1 and 2 of GH
are largely composed of the same residues suggest that one GHR cannot bind more
than one GH molecule. Receptor dimerization is crucial for signal transduction
since a hGH antagonist, G120R, still being able to bind to the first GHR via its site
1 but defective in its site 2 to induce dimerization, cannot transduce signal, being
however internalized as efficiently as the wild type ligand (48, 49). Such com-
pounds can be used to compete with the natural ligand to transduce signal and be
designed for therapeutic use (50).
GHR dimerization & JAK2 activation
Although the GHR and other cytokine receptors do not possess intrinsic tyrosine
kinase activity, GH binding to its receptor results in rapid tyrosine phosphorylation
of multiple cellular proteins due to the activation of GHR-associated tyrosine kina-
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ses of the JAK family. The ability to associate with and activate tyrosine kinases is
essential to propagate many if not most intracellular signals (e.g. the proliferation,
gene induction, and activation-signaling molecules like phosphatidylinositol 3
(PI3)-kinase, MAP kinase and ras). The JAK kinases represent a distinct family of
soluble tyrosine kinases that have been strongly implicated in the signal transduc-
tion of many members of the cytokine family. The four members of the family,
which include Tyrk2, JAK1, JAK2, and JAK3, have molecular weights ranging
from 125-135 kDa (for review see Ref. 51). Among known members of the JAK
family, JAK2 is the main kinase activated by the GH-GHR complex and considered
the initiating step in GHR signal transduction (10). Activation of JAK2 by GH was
shown in various cell systems and in vivo in liver, heart, kidney, and adipose tissue
(52). Some activation of JAK1 was also described (53) and another high molecular
weight JAK2 antigenically related protein was reported to be phosphorylated upon
GH stimulation (54). A direct comparison of the four JAK family members revealed
the presence of seven highly conserved domains (JH1-JH7) and a sequence identi-
ty of 35-45% (55). The family members consist of two kinase-related domains JH1
and JH2 and do not contain any SH2 or SH3 domains. The importance and function
of  the other five domains remain poorly understood. Only the most carboxyl-ter-
minal domain is believed to be functional, while the N-terminal region is thought to
be involved in GHR association, as suggested by the activity of deletion mutants of
the tyrosine kinase. Deletion of the kinase domain eliminated functional coupling
but not physical association of JAK2 with the GHR (56).
Studies using mutated and truncated GHRs have indicated that box-1, the proline-
rich region in the cytoplasmic domain of the GHR, is necessary for GH-dependent
association and activation of JAK2 with the GHR, (57, 58, 59). No specific amino
acid within box-1 is essential for the association between the receptor and JAK2.
Mutation of each individual proline residue in box-1 or the simultaneous mutation
of the first two prolines did not impair the kinase association. However, a specific
secondary structure of the receptor is required, in which simultaneous mutation of
the last two prolines or of the three hydrophobic residues (isoleucine; leucine and
valine into threonine) abolishes the capacity of the receptor to interact with and to
activate JAK2 (60). The box-1 sequence of the GHR is very similar to proline-rich
SH3 domains. However, as mentioned above, no SH3 domain has been identified
in JAK2, and the existence of an SH3-containing adaptor protein could mediate or
facilitate the association between cytokine receptors and JAK kinases. The first 46
residues of the GHR containing the box-1 are sufficient to induce some JAK2 acti-
vation, but maximal activity of this kinase requires downstream residues in the half-
proximal transmembrane part of the GHR cytoplasmic domain. This region appears
to stabilize the interaction between the receptor and JAK2.
Normally, JAK kinases are thought to be catalytically inactive in resting cells being
however associated with the cytoplasmic domains of receptor chains. Upon ligand-
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stimulation, the GHR becomes dimerized, increasing the affinity of each GHR for
JAK2. This brings two JAK2 molecules into close proximity allowing each JAK2
to transphosphorylate one or more tyrosines within the kinase domain of the paired
JAK2, thereby activating the JAK2 kinase. It is important to note that, while multi-
ple ligands activate the same JAK, they do not necessarily activate it to the same
extent and with the same time course in the same cell line. 
GHR signaling pathways
As mentioned above, upon GH binding to its receptor, activation of JAK2 is rapid
and transient. Once activated, JAK2 phosphorylates the GHR on multiple tyrosine
residues providing docking sites for other signaling molecules (61). JAK2 transient
phosphorylation can reach a maximal activity at 5-20 min depending on cellular
types and return to basal levels after 60 min of stimulation. JAK2 activation appears
to be sufficient to mediate some of the effects of GH, such as stimulation of cell pro-
liferation and the activation of signaling molecules involved in this effect (57).
JAK2 contains 48 tyrosines, all which might become phosphorylated upon GH,
suggesting that this kinase can interact with multiple signaling molecules (62).
Among the direct substrates of JAK2 are several docking proteins involved in the
Ras/MAP kinase pathway, the STAT proteins (signal transducers and activators of
transcription), as well as the insulin receptor substrate proteins IRS-1 and IRS-2,
which initiate the PI-3 kinase pathway (reviewed in: 63). Another protein identified
as a JAK2 substrate was SH2-Bβ which function is still not established (64). So far,
only the GH-dependent calcium transport appears to involve a pathway that is inde-
pendent of JAK2 activation (65). The GHR has several conserved tyrosine residues
in its intracellular domain that can become phosphorylated and appear to play a role
in different actions of GHR. Other GH effects like GH-dependent expression of the
insulin gene or the serine protease inhibitor (Spi) 2.1 gene require additional
sequences in the GHR cytoplasmic domain (66, 67). In a more distal C-terminal part
of the GHR cytoplasmic domain, the tyrosine phosphorylation of residues Y487,
Y534, Y566 or Y627 of pig GHR is required for GH-induced tyrosine phosphory-
lation of STAT5 (68), while Y333 and/or Y338 in rat GHR appears to be required
for GH-stimulated lipid and protein synthesis (69) and maximal activation of STATs
1, 3 and 5 (53). 
STATs
STAT proteins are a family of transcription factors that couple ligand binding to cel-
lular receptors with the activation of gene transcription (70). Currently, the
sequence of seven genes from mammals that encode STAT family members have
been reported (reviewed in: 71, 72). This family contains many conserved features:
(a) the N-terminal 140 amino acids are conserved; (b) the presence of a leucine-rich
heptad repeat region located approximately 200 residues from the N-terminus (dele-
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tion of the region results in STAT inactivation); (c) an SH2 domain important for
binding to phosphorylated tyrosine residues; (d) a tyrosine residue located at the C-
terminus that is a substrate for JAK2; and (e) a serine phosphorylation site (73). GH
was found to be able to activate STAT1, STAT3 and both isoforms of STAT5,
STAT5a and STAT5b (53). STAT1 was initially identified as a transcription factor
induced by interferons (74), STAT3/acute phase response factor (APRF) identified
in IL-6 and LIF signaling (75, 76, 77), and STAT5 was first cloned as a prolactin-
responsive factor, initially named mammary gland factor (78). Upon JAK2 tyrosine
phosphorylation, cytoplasmic STAT proteins are recruited through their SH2
domain in the complex GHR/JAK2 kinase and are subsequently phosphorylated by
JAK2 on their conserved C-terminal tyrosine. Activated STATs homo- or he-
terodimerize with other STATs and/or non STAT proteins, presumably by interac-
tions involving the SH2 and SH3 domains of the STAT proteins, translocate to the
nucleus, bind DNA and activate transcription of target genes (79). STAT1 and
STAT3 are phosphorylated in response to GH and bind to the c-sis-inducible ele-
ment (SIE) of the c-fos promoter/enhancer (80, 81). Similarly, GH promotes the
binding of STAT5 to the GH-responsive element 2 (GHRE-2) in the promoter
region of the Spi 2.1 gene (67, 82). Activation of the different STATs by GH differs
among tissues and cell lines. In 3T3-F442A fibroblasts, in liver from hypophylsec-
tomized rats treated with GH and CHO cells expressing recombinant GHR, it was
shown that GH induced tyrosine phosphorylation of both STAT1, 2 and 5 (53, 83).
High levels of unphosphorylated STAT1 and STAT3 were found in the liver in both
male and female rats, whereas tyrosine phosphorylated STAT5b was present at a
high steady-state level only in male nuclear extracts (84). In CHO cells transfected
with rabbit GHR, GH induced the formation of complexes consisting of STAT5a
and the MAP kinase ERK2, and STAT5a and STAT5b association with the adaptor
protein SHC (85).
The regions of the GHR required for activation of the different STATs has been
mapped. STAT1, STAT3 and STAT5 all require the membrane proximal part of the
GHR including box-1, and therefore JAK2 activation by GH in order to become
phosphorylated and activated (86, 80, 81, 53). Furthermore, STAT5 activation in
response to GH most likely results as a consequence of STAT5 binding to multiple
binding sites within the GHR, like phosphorylated tyrosines that are present within
both the C-terminal half and N-terminal half of the cytoplasmic domain of the GHR
(87, 61, 88). In pGHR, it was found that Y322, Y487, Y534, Y566, and Y627 are
phosphorylated in response to GH (61). In addition, tyrosine residues in the C-ter-
minal region of the GHR transfected in CHO cells are necessary for serine phos-
phorylation of the STAT5a isoform, which then associates with other proteins, like
ERK2, and both STAT5 isoforms interact with the serine-threonine kinase Akt-1,
indicating the importance of serine phosphorylation cascades in GH signaling (85).
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MAP kinases
The main signaling pathways stimulated by GH are shown in Fig 1. Two such pro-
teins that are activated by GH are the MAP kinases ERK1 and ERK2 (89, 90, 91).
MAP kinases are a family of the serine/threonine/tyrosine kinases that mediate both
cellular growth and differentiation upon stimulation by many growth factors and
hormones (reviewed in: 92). One pathway leading to MAP kinase activation
involves the SHC tyrosine phosphorylation (87), followed by the sequential recruit-
ment of Grb2, Son-of-sevenless (Sos), Ras, Raf, and MAP kinase kinase (MEK)
(93, 94). The binding of SHC through its SH2 domain to phosphorylated residues
in both JAK2 and the GHR is the first step in GH-mediated MAPK activation (87).
GH rapidly and transiently stimulates tyrosine phosphorylation of the 46-, 52-, and
66-kDa known isoforms of SHC (87). It is thought that JAK2 phosphorylates SHC,
as GHR mutants that fail to bind and activate JAK2 are unable to phosphorylate
SHC and activate ERK1 and ERK2 (87, 59). Active SHC then interacts with and
activates growth factor receptor bound to Grb2. Grb2 can then activate Sos, which
in turn activates RAS, RAF, MEK and MAPK (94). MAPK activation by GH may
be mediated via activation of the epidermal growth factor (EGF) receptor (95). It
has been reported that EGFR was phosphorylated by JAK2 and may act as a dock-
ing protein for Grb2. This finding is one example of cross-talk between membrane
receptors of different families.
Insulin Receptor Substrates-1 and -2 (IRS-1 and IRS-2) and
Phosphatidylinositol 3-kinase (PI 3-K)
Upon GH stimulation, rapid insulin-like effects (read above, GH) like increased
amino acid transport, glucose transport and lipogenesis occur (28). The finding that
GH can interact with IRS-1 and induce its phosphorylation was observed in rat
adipocytes, in 3T3-F442A fibroblasts or in CHO cells expressing GHR (96). IRS-2
was also reported to be associated to GHR complexes (51). IRSs were originally
identified as signaling molecules for insulin and the closely related IGF. IRS-1 and
IRS-2 are large cytosolic proteins (160-180 kDa) that appear to serve as mobile
adapter proteins. They are phosphorylated on multiple tyrosines in response to
insulin stimulation and form high-affinity binding sites for signaling molecules like
the p85 regulatory subunit of phosphatidylinositol kinase (PI 3-kinase, which is
activated upon p85 binding to IRS proteins) (97, 51, 98), the SH2 domain-contain-
ing tyrosine phosphatase two (SHP2) (51, 99) the Src family kinase fyn, Nck, and
Grb2 (100, 101, 102). 
The nature of the GH-stimulated interaction with IRS-1 is still not clearly under-
stood. Studies using truncated and mutated GHRs expressed in CHO cells showed
that the regions of the receptor required for tyrosine phosphorylation of IRS-1/IRS-
2 were the same as that required for JAK2 activation (51). Tyrosine phosphoryla-
tion of IRS-1 and IRS-2 is dependent on JAK2 activation and interaction of the
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GHR-JAK2 complex with IRS-1 and IRS-2 occurs through activated JAK2 either
directly or via an intermediary protein. GH promotes the binding of the 85-kDa re-
gulatory subunit of PI 3-kinase to IRS-1 and IRS-2 (51). PI 3-kinase is implicated
in several pathways, including DNA synthesis, glucose uptake, cell cycle regulation
via p70 ribosomal subunit kinase (rsk) activation (103), and inhibition of apoptosis
via Akt serine threonine kinase (104). Most cytokine receptors induce the recruit-
ment of PI 3-kinase in the activated cytokine receptor complex, the interaction
being direct or indirect. In the case of the GHR, PI 3-kinase could associate with
either the receptor (105), JAK2, or IRS-1 and IRS-2. However, PI 3-kinase is acti-
vated but not tyrosine phosphorylated under GH stimulation. The role of PI 3-
kinase in GHR signaling could partially explain the insulin-like effects of GH as
wortmannin, a PI 3-kinase inhibitor, blocks the ability of GH to stimulate lipid syn-
thesis (106). 
· PLC, PKC, Ca2+ pathways
GH has been found to activate protein kinase C (PKC) through the phospholipase
C (PLC) signal transduction pathway (105). Activation of PKC by GH is thought to
stimulate lipogenesis (107), induce c-fos expression (108), increase intracellular
Ca2+ concentration (109), and stimulate binding of nuclear protein to C/EBP
oligonucleotide (110). It is still not clear whether PKC is involved in the activation
of MAPKs and p90RSK (89, 90, 91). PKC is a family member of serine/threonine
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kinases consisting of at least 12 isoforms that activate several proteins, and impor-
tant regulators of cellular growth, differentiation and metabolism (111, 112). For
most of the PKC isoforms, activation and translocation from the cytosol to the cel-
lular membrane is mediated by the second messenger Ca2+ and/or 1,2-diacylgly-
cerol (DAG). GH transiently induces activation of DAG, an activator of PKC, in
multiple cell types (113, 114), that can then bind, recruit, and stimulate PKC (115).
Activation of the α-, β-, and γ-isoforms requires Ca2+ while the ε-, δ-, ν-, ζ-, and θ-
isoforms are Ca2+ independent. The inositol 1,4,5-trisphosphate (IP3) pathway that
generates both Ca2+ and DAG can activate PKC isoforms distinct from the isoforms
activated following phospholipase C-mediated or phospholipase D-mediated
hydrolysis of phosphatidylcholine with generation of just DAG (reviewed in: 111,
112). Phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trispho-
sphate, byproducts of PI 3-kinase, have been shown to activate the Ca2+ independ-
ent PKC isoforms ε-, δ-, and ν- (116). The findings that GH induces translocation
of the ε-isoform of PKC from the cytoplasm to the plasma membrane in 3T3-F442A
fibroblasts (117) and that wortmannin inhibits GH-dependent DAG formation in rat
adipocytes (118) raise the possibility that in some cell types GH activation of PKC
may involve IRS-1, IRS2, and PI 3-kinase. Ca2+ increase by GH seems to be
dependent on L-type calcium channel activation by a mechanism including phos-
pholipid hydrolysis and PKC activation (as mentioned above). Ca2+ seems to be
important for activation of some GH-induced genes such as the Spi2.1 gene and the
effects of GH on metabolism in adipocytes (119, 65). Ca2+ activation is until now
the only pathway activated by GH that does not require Box-1 but only the C-ter-
minal part of the GHR (65).
Negative Regulators of GH Signaling
Phosphatases
Pre-incubation with pervanadate, which inhibits phosphatase activities, resulted in
a prolonged JAK2 and STAT5 tyrosine phosphorylation (120), indicating that phos-
phatases are involved in the inactivation process. Upon truncation of the C-termi-
nal region of the GHR tail, JAK2 phosphorylation was sustained and STAT3 and
IRS-1 activation enhanced (121). This suggests that a phosphatase may interact
with the C-terminal cytoplasmic domain of the GHR. The tyrosine phosphatase
SHP-1 (also known as HCP, SH-PTP-1, and PTP1C) was found to interact with
JAK2 and dephosphorylate the kinase (122, 123). SHP-1 is a SH2 domain-contain-
ing tyrosine phosphatase that is expressed primarily in haematopoietic cells.
However, since SHP-1 does not associate with the GHR, and as downregulation of
JAK2 still occurs in the liver of knockout SHP-1 mice (122), it is likely that ano-
ther mechanism contributes to the downregulation of JAK2 activation. SHP-2,
another phosphatase, was found to associate with the GHR (124) and bind to JAK2,
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but no dephosphorylation of JAK2 by SHP-2 was demonstrated (125). On the con-
trary, SHP-2 was found to positively regulate GHR signaling (124). Recently, the
transmembrane PTPase CD45, a key regulator of antigen receptor signaling in T
and B cells (126), was found to supress JAK kinases and negatively regulate
cytokine receptor signaling (127). Targeted disruption of the cd45 gene lead to
enhanced cytokine and interferon-receptor-mediated activation of JAKs and STAT
proteins. In vitro, CD45 directly dephosphorylated and bound JAKs and was shown
to negatively regulate interleukin-3-mediated cellular proliferation, erythropoietin-
dependent haematopoieisis and antiviral responses in vitro and in vivo (127).
Kinase inhibitors such as H7, which inhibits serine threonine kinases, resulted in
sustained JAK2/STAT activation, suggesting that besides protein dephosphoryla-
tion, protein phosphorylation is also required. Furthermore, both inhibition of pro-
tein synthesis with cycloheximide and inhibition of protein degradation with pro-
teasome inhibitors such as MG132 induced prolongation of the signal (128, 120).
Several processes are probably involved in GHR signal downregulation that require
both activation of phosphatases, activation of kinases, protein degradation and pro-
tein biosynthesis. Therefore, other molecules that could bind to the C-terminal
region of the GHR would contribute to signal downregulation.
SOCS proteins
A recent identified new family of negative regulators of cytokine signaling is the
suppressor of cytokine signaling (SOCS). The SOCS family, including the immedi-
ate early gene CIS (cytokine inhibitor of signaling), comprises of at least eight pro-
teins (SOCS-1 to SOCS-7, CIS) with similar structures (129, 130, 131, 132, 133).
The SOCS proteins contain a variable region at the N-terminus, a centrally located
SH2 domain mediating binding to phosphotyrosine residues in target proteins, and
a region of homology at the C-terminus termed the SOCS box (130). The SOCS box
is a region of approximately 40 amino acids which is unrelated to the sequence of
other motifs and is of unknown function (130, 132). Searches on DNA databases for
sequences homologous to SOCS box have identified 12 proteins containing this
motif (132, 134). Besides the SOCS proteins, three new families of proteins con-
taining either WD-40 repeats, SPRY domains or ankyrin repeats N-terminal to the
SOCS box were described (132). The function of these proteins is still unknown.
Furthermore, a class of small GTPases contains a SOCS box motif (132).
Expression of these proteins exhibit unique tissue-specific and time-dependent
responses to a broad range of cytokines, with different stimulation kinetics between
the different SOCS genes, that is mediated, at least in part, by STAT proteins.
Expression of the CIS gene is modulated by STAT5 and STAT3 is important for
SOCS-1 expression (135, 136), forming a classical feedback loop that regulates
cytokine signal transduction. CIS was found to bind to the tyrosine phosphorylated
Epo and IL-3 receptors and block STAT5 phosphorylation and downstream STAT5-
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dependent transcriptional responses and, in this way, to supress proliferation of
hematopoietic cells in response to IL-3 (137, 135). In contrast, SOCS-1 binds to the
phosphorylated JH1 domain of JAK2 and this association is likely to be mediated,
at least in part, by its SH2 domain, although this interaction alone is insufficient for
inhibition of a biological response (138). SOCS/CIS mRNA expression can be
induced in liver cells in response to a pulse of GH (139, 140), and both SOCS-1 and
SOCS-3 were found to inhibit GH-induced STAT5-dependent transcriptional
responses in transfected cells (139, 141). Expression of other SOCS genes, SOCS-
2 and CIS, were also up-regulated by GH, although to a lesser extent than SOCS-3
and with differing kinetics (139). SOCS/CIS proteins inhibit GH-stimulated tyro-
sine phosphorylation of STAT5b and STAT5b-dependent gene transcription by three
distinct mechanisms, distinguished by their targets within the GHR-JAK2 signaling
complex. GHR tyrosine residues 333 and 338, required for GH-stimulated lipoge-
nesis and protein synthesis (69), are phosphorylated in response to GH stimulation
(142) but are not obligatory for GH-stimulated STAT5b activation (69), and are
known to play a key role in mediating the inhibitory effects of SOCS-3 on GH si-
gnaling (143). The binding of SOCS-3 to GHR tyrosines 333/338 could inhibit
JAK2 signaling to STAT5 by interfering with JAK2 binding to the adjacent GHR
box-1 region (residues 298-311), thereby raising the Kd of the receptor-kinase com-
plex (143). SOCS-1 acts at the level of JAK2 tyrosine kinase, as JAK2 tyrosine
phosphorylation is strongly inhibited by SOCS-1 protein (143). SOCS-1 inhibition
of JAK2 kinase activity requires binding interactions between SOCS-1's SH2
domain and tyrosine 1007 within JAK2's kinase activation loop (144). The inhibi-
tion of JAK2 activity additionally requires a 13-residue "kinase inhibitory peptide"
that is immediately NH2-terminal to SOCS-1's extended SH2 domain, and is pro-
posed to function as an inhibitory, non-phosphorylable pseudosubstrate of JAK2
(144, 145). Furthermore, SOCS-1 can bind to the 80 COOH-terminal cytoplasmic
residues of GHR, even in the absence of tyrosine phosphorylation, suggesting that
it may be associated with unstimulated receptor molecules. Possibly, the binding of
SOCS-1 to these GHR sequences may serve to correctly orient SOCS-1 or perhaps
increase its affinity for the receptor-kinase signaling complex (143). In the case of
CIS and SOCS-2, but not SOCS-3, GHR residues 540-620 were sufficient for
SOCS/CIS binding to the receptor (143). GH stimulates phosphorylation of two
tyrosines within this region (rat GHR tyr 566 and 627; hGHR tyr 548 and 609), both
of which provide functional docking sites for STAT5 (88). The inhibition by CIS or
SOCS-2 of GHR-JAK2 signaling to STAT5 could result from direct competition
between STAT5 and either CIS or SOCS-2 for tyrosine-phosphorylated binding
sites on GHR. Alternatively, the inhibition of GH signaling by CIS or SOCS-2 could
involve SOCS/CIS protein ubiquitination followed by degradation of the the
SOCS/CIS-bound GHR-JAK2 complex. It has been reported that the SOCS box
binds elongins B and C (134). The elongin BC complex has been shown to bind
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elongin A to form an active transcriptional elongation complex or to the von Hippel
Lindau (VHL) tumor suppressor protein (146, 147). The VHL/elongin B-C (VCB)
complex also contains a putative E3 ubiquitin ligase (Cullin-2) that may target
VHL-binding proteins to destruction by the proteasome (148). The interaction sites
on elongin A and VHL that interact with elongin C are homologous to the N-termi-
nal half of SOCS box (147), suggesting that the primary interaction is between the
SOCS box and elongin C (149). Interestingly, elongin B contains an ubiquitin-like
(UBL) sequence at its N-terminus (150), suggesting a model for the action of the
SOCS proteins. First, the N-terminal and SH2 domains of SOCS-1 and SOCS-3, at
least, are required for recognition and binding to activated JAKs. On the other hand,
the SOCS box brings into this complex elongins B and C. The model suggests that,
either through direct interactions of the elongin B UBL domain with the proteasome
or through associated Cullin-2-induced ubiquitination of substrates and subsequent
proteosomal association, JAK2 and the associated SOCS proteins may be destroyed
(149). In favor to this model, it was demonstrated that CIS and SOCS-1 are degra-
ded in a proteasome-dependent manner (149, 151). SOCS-1 was shown to program
the hematopoietic specific guanine nucleotide exchange factor, VAV, for ubiquitin
/proteasome-mediated degradation by acting as a substrate-specific recognition
component of a VCB-like ubiquitin ligase complex (151). Furthermore, CIS was
shown to become ubiquitinated and its degradation was inhibited in presence of
proteasome inhibitors upon EPOR stimulation (152). It was further shown that CIS
inhibits GHR-JAK2 signaling by two distinct mechanisms: (1) a partial inhibition
that is decreased at elevated STAT5b levels and may involve competition between
CIS and STAT5b for common GHR cytoplasmic tail phosphotyrosine-binding sites;
and by a time-dependent inhibition, not seen with SOCS-3, that involves protea-
some action (153); (2) GH was shown to induce degradation of CIS, but not SOCS-
Figure 3. Model of SOCS action
Model of the interaction of SOCS-box containing proteins with elongins C and B (A) and comparison
with the PULC assembled by F box-containg proteins (B). Black images represent negative regulators
of GHR signaling
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3, and the proteasome inhibitor MG132 blocked CIS degradation as well as it
inhibitory action on STAT5b signaling (153). Proteasome-dependent degradation of
CIS, most likely in the form of a (GHR-JAK2)-CIS complex, is therefore proposed
to be an important step in the time-dependent CIS inhibition mechanism. The down-
regulation of GHR-JAK2 signaling to STAT5b seen in GH-treated cells, as well as
for cells treated with IL-3, IL-2 and EPO, could be prevented by treatment with dif-
ferent proteasome inhibitors (154, 155, 152), sugges-ting that SOCS proteins are
key mediators of cytokine-JAK-STAT desensitization response seen in cells and tis-
sues exposed to the different cytokines. Recently, it was demonstrated that supres-
sion of JAK2 activity was dependent on SOCS-1, where its SOCS box mediated
proteasomal degradation of JAK2 rather than JAK2 kinase inhibition (156).
Degradation of JAK2 depended on its phosphorylation and its high-affinity binding
with SOCS-1 through the kinase inhibitory region and the SH2 domain. The SOCS
box of SOCS-1 was found to interact with the E3 Cullin-2 and promoted ubiquiti-
nation of JAK2. This interaction demonstrated the substrate-specific E3 ubiquitin-
ligase-like activity of SOCS-1 for activated JAK2, providing a novel strategy for
the supression of oncogenic tyrosine kinases (156).
The Ubiquitin-Proteasome System
Ubiquitin conjugation: E1, E2, E3 enzymes 
Ubiquitin ia a 76-amino-acid globular protein that is highly conserved throughout
eukaryotes, with only three amino-acid changes from yeast to human. Ubiquitin
conjugation to target proteins -ubiquitination or ubiquitylation- is essential for the
degradation of proteins whose levels are regulated either constitutively or in
response to changes in the cellular environment. Ubiquitin-mediated proteolysis of
a variety of cellular proteins plays an important role in many basic cellular proces-
ses. Among these are regulation of cell cycle and division (157, 158, 159), diffe-ren-
tiation and development (160, 161, 162, 163), modulation of cell-surface receptors
(164, 165), involvement in the intracellular response to stress and extracellular
effectors (166, 167), apoptosis (168, 169, 170), ion channels and the secretory path-
way (protein transport) (171, 165), morphogenesis of neuronal networks (172),
transcriptional regulation and signal transduction (173, 164, 174), transcriptional
silencing, DNA repair (175, 176), long-term memory, circadian rhythms, quality
control in the endoplasmic reticulum (ER) (177, 178), regulation of the immune and
inflammatory responses (antigen processing) (179, 180, 181), and biogenesis of
organelles (182).
Ubiquitination involves a three-step cascade mechanism. First, a ubiquitin-activa-
ting enzyme, E1, activates ubiquitin by forming a high-energy thiol-ester bond with
the carboxyl-terminal glycine of ubiquitin in an ATP-dependent process. One of
several E2 enzymes (ubiquitin-conjugating enzymes, UBCs) accepts ubiquitin from
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the E1~S~ubiquitin intermediate by a trans-thiolation reaction, involving the car-
boxyl terminus of ubiquitin. An ubiquitin protein ligase, E3, catalyses the transfer
of ubiquitin from the E2~S~ubiquitin intermediate to the ε-amino group of a lysine
residue on the substrate. As E3 enzymes specifically bind protein substrates, they
play an important role in selection of proteins for degradation. In successive reac-
tions, a polyubiquitin chain is synthesized by processive transfer of ubiquitin moi-
eties to Lys-48 of the previous already conjugated ubiquitin molecule (183).
Polyubiquitinated proteins are then recognized and degraded by the downstream
26S proteasome complex, and free and reutilizable ubiquitin is released (reviewed
in: 184, 185, 186). In many cases, however, E2 transfers activated ubiquitin direc-
tly to the protein substrate. Thus, E2 enzymes also play an important role in sub-
strate recognition, although, in most cases, this modification is of the monoubiqui-
tin type and is probably not involved in targeting the substrate for degradation.
E1
E1 enzyme is a homodimer with an apparent molecular mass of 210 kDa that is
composed of two 105-kDa subunits (187). E1 is strongly conserved in evolution,
where the human and yeast proteins are 53% identical and 73% homologous. The
yeast genome encodes for a single ubiquitin-activating enzyme, UBA1, and inacti-
vation of this gene is known to be lethal. E1 is highly concentrated in both yeast
(188) and mammalian cell nuclei (189). Nuclear localization signals allow cell-
cycle-regulated nuclear localization and phosphorylation, with an increase in
nuclear distribution in G2 phase (190). The finding that cells expressing a tempe-
26
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rature-sensitive E1 undergo cell-cycle arrest provided the first evidence for the
physiological significance of ubiquitination (191). However, its role in the nucleus
is still not clear. E1 may be involved in the ubiquitination of specific nuclear pro-
teins such as histones or in the degradation of other nuclear proteins (192).
E2
Thirteen E2s have been isolated from yeast (termed Ubc1-13) and there are at least
25 more E2s described in other eukaryotes (175, 193). All known E2s share a 35%
conservative domain of 14-16-kDa that contains the Cys residue required for the
formation of ubiquitin-E2 thiol ester intermediate. Some of the E2 proteins consist
almost entirely of this conserved domain, while others have C-terminal extensions
that are either neutral, or highly acidic, and that promote interaction with substrates
or interactions with specific E3s. Each E2 interacts with a number of E3 ligases,
thus being involved in targeting numerous substrates, and the specific functions of
E2s are due to their association with distinct E3s (194). Some E2s are involved in
specific cellular processes while the role of others is still unclear. One group of E2
enzymes is involved in multiple ubiquitination of cellular proteins that signals them
for degradation. Such enzymes are, for instance, UBC4 and UBC5, involved in the
degradation of the bulk of short-lived and abnormal proteins. They are also required
to enable the cell to withstand stress, such as heat shock or exposure to cadmium,
probably by mediating degradation of denatured proteins generated under these
conditions. A mammalian E2 homologous to yeast UBC4/UBC5 is involved in
polyubiquitination and degradation of p53 and of many other proteins as well. The
yeast UBC2/RAD6 is involved in degradation of "N-end rule" substrates (see
below) and also in DNA repair (185). UBC3/CDC34 is required for G1 to S transi-
tion, probably via degradation of certain cell-cycle regulators. Other E2s are mem-
brane-associated and may be involved in degradation of abnormal or virus-targeted
ER proteins. Experiments in cell free systems showed that certain E2 enzymes are
involved in E3-independent monoubiquitination that does not target proteins for
degradation. However, their physiological significance is not clear (194).
E3
E3s bind the target substrates, either directly or indirectly, via ancillary proteins, and
catalyze transfer of ubiquitin from a thiolester intermediate on E2 or E3 to an amide
linkage with the substrate or with a polyubiquitin chain already anchored to it. Until
now, only a few E3s were actually discovered. Despite the importance of E3s in
determining the specificity of the system, there is no sequence homology among
different E3s, and the frequent association of these enzymes with multisubunit com-
plexes in which the identity of the ligase subunit is not known, makes these proteins
difficult to study.
Until now, three families of E3s were described:
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(i) The main N-end rule E3, E3α, and its yeast counterpart UBR1, contain two dis-
tinct sites that recognize either basic (Type I) or bulky-hydrophobic (Type II) N-ter-
minal residues of their substrates. However, they also recognize non-N-end rule
substrates such as N-α-acetylated proteins that bind via another site (186, 195). 
(ii) The second group of E3s, HECT E3s, were first discovered when oncogenic
strains of human papillomavirus (HPV) were encoding isoforms of a protein called
E6, which specifically inactivated the tumor suppressor protein p53. E6 functions
as an adaptor between E6-associated protein (E6-AP), a cellular partner for E6, and
p53, allowing E6-AP to ubiquitinate p53 (196). E6-AP and a family of proteins
closely related to E6-AP in a 350-residue region at their carboxyl termini, termed
the HECT domain, were further identified (197). This domain includes a conserved
cysteine that forms a covalent thiol-ester intermediate with ubiquitin (197). With the
exception of E6-AP, the HECT family of E3s contains N-terminal WW domains.
These domains are known to be involved in protein-protein interactions, via pro-
line-rich motifs of proteins, and in targeting substrates for ubiquitination (198).
Most of these WW domain HECT3s include an N-terminal C2 domain, known to
mediate translocation to the plasma membrane in response to increases in intracel-
lular Ca2+, like for instance Nedd4 (199). Nedd4 is one rare example of an E3
enzyme ubiquitinating a membrane protein, the kidney epithelial sodium channel
(ENaC) (200). Nedd4 binds directly through its WW domain to ENaC and induces
its ubiquitination and degradation in the lysosome, leading to downregulation of the
number of active channels. Mutation of proline-rich regions of ENaC, known to
interact with Nedd4, causes Liddle syndrome, an inherited form of hypertension in
which ENaC activity is increased due to the inability of Nedd4 to downregulate
ENaC (198, 201, 202).
(iii) A third type of ligase are the RING finger-containing E3s (203, 204). RING fin-
gers have been defined by a pattern of conserved Cys and His residues that form a
cross-brace structure that probably binds two zinc cations (205). This group of pro-
teins is rather large, with molecules forming single and multisubunit E3s. The sin-
gle-subunit E3s contain both a RING finger domain and the substrate binding and
recognition site on the same molecule. Examples of these proteins include the onco-
protein Mdm2, responsible of ubiquitinating p53 (206, 207), the proto-oncoprotein
c-Cbl, responsible for ubiquitinating growth factor receptors (208, 209, 210), and
the inhibitors of apoptosis (IAPs) (211). Multisubunit E3s consist of a small RING
finger protein and a member of the cullin family of proteins as well as other sub-
units, some of which recognize substrates. Among this E3 group are the anaphase
promoting complex (APC)/cyclosome which includes at least 12 distinct subunits
and is involved in degradation of cell cycle regulators (212, 213, 214); the Skp1-
Cullin/Cdc53-F-box protein (SCF)-RING finger complexes involved in degradation
of signal- and cell cycle-induced phosphorylated proteins (215); and the von-Hippel
Lindau (pVHL)-Elongins B and C (VBC)-Cul2-RING finger complex (216, 217,
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218) that targets hypoxia-inducible transcription factor 1α (HIF-α) and possibly
JAKs for degradation (219, 151), see above: SOCS proteins). The APC complex has
an ubiquitin ligase activity specific for cell-cycle regulators, like for instance mitot-
ic cyclins, some anaphase inhibitors and spindle-associated proteins, that contain a
nine amino acid motif termed the "destruction box" and are degraded during mito-
sis. Normally, the complex is only activated at the end of mitosis by phosphoryla-
tion that is mediated by the cyclin-B/cyclin-dependent kinase (CDK)1 complex M-
phase promoting factor (MPF) (220). The SCF E3s recognize and ubiquitinate sev-
eral phosphoproteins, with the key substrate recognition element being dependent
on the F-box protein component of the complex (221).
The SCF complexes act along with the E2 Cdc34/Ubc3, with the following struc-
ture: E2-Rbx1/Roc1-Cdc53/Cullin-1-Skp1-F-box protein-protein substrate. There
are examples in which one F-box protein is able to recognize different substrates,
as in the case for β-transducin-repeat-containing protein (βTRCP) that recognizes
both β-catenin (222), IkBα (223), and HIV-1-Vpu (224). In spite of the fact that the
plasma membrane Vpu undergoes phosphorylation and recruits E3, it is the HIV
receptor CD4 that is targeted for degradation in the ER membrane following for-
mation of a CD4-Vpu-SCF complex. Furthermore, some F-box proteins are them-
selves ubiquitinated and degraded, suggesting a mechanism of regulating SCF func-
tion and facilitating proteasomal targeting of associated target proteins. In contrast,
the ubiquitination of the transcription factor Met4 by SCFMet30 serves to regulate
its activity but not its proteolysis (225). The VBC complex is quite comparable to
the SCF complex, containing Elongins B and C, Cullin 2, and pVHL, in addition to
RBX1/Roc1, the same RING finger protein that is shared by SCF complexes (219).
Skp1 is replaced by the dimer of elongin B, which has homology with Skp1, and
elongin C, which is an UDP. The substrate recognizing subunit has not yet been
identified, being pVHL the best candidate. Similar to the SCF complex, it is possi-
ble that more than one substrate recognition proteins are involved in BC-Cul2-Rbx1
E3 complexes. Analogous to the F box, the VHL protein contains a SOCS box that
interacts with the core of this E3. It might be that other SOCS-containing proteins
can replace the VHL and allow for recognition of other specific substrates (134, see
above: SOCS proteins). 
E4, U-box containing proteins, and deubiquitinating enzymes (DUBs)
In yeast, it was found that an ubiquitin chain elongation factor, E4, binds to ubiqui-
tin moieties of pre-formed short conjugates and catalyses ubiquitin chain elongation
in conjunction with E1, E2, and E3 (226). This new family of proteins shares a mod-
ified version of RING finger designated U box that lacks the metal-chelating
residues typical of RING fingers (227). The function of the U box is, however, still
not clear. Possibly, it might recruit E2 to the conjugation machinery or bind to the
short ubiquitin chain attached to the substrate protein. One example is the CHIP
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protein, known to be involved in both the degradation of the cystic fibrosis trans-
membrane conductance regulator (CFTR), which is a chloride ion channel, and the
glucocorticoid receptor together with the co-chaperones Hsc70 and Hsp90, respec-
tively (228, 229). 
Covalent attachment of ubiquitin to proteins is a reversible process, through the
action of deubiquitinating enzymes (DUBs). There are 19 yeast DUBs and several
more in mammals discovered until now. These enzymes are cystein proteases that
specifically hydrolyze the amide bond immediately after the C-terminal residue.
DUBs belong to a large and diverse family of enzymes divided as UHCs (ubiquitin
carboxyl-terminal hydrolases) and UBPs (ubiquitin-specific processing enzymes)
(230, 231). UHCs are 20-30 kDa enzymes that remove short or flexible peptide
chains from the C-terminus of ubiquitin. UBPs, on the other hand, are enzymes of
about 100 kDa, thought to remove ubiquitin ubiquitin form larger proteins, and are
involved in the disassembly of multi-ubiquitin chains. Both types of DUBs play
several roles in maintaining the steady-state levels of free ubiquitin and in affecting
the stability of ubiquitin-conjugated proteins (232, 230, 231). For instance, genera-
tion of ubiquitin, recycling of ubiquitin, maintaining proper levels of ubiquitin in
the cell, editing polyubiquitin chains, and helping in proteasome-dependent degra-
dation and proteasome-dependent endocytosis, are processes regulated by DUBs
(233, 234). 
The Proteasome 
The proteasome is a 700,000-dalton (~2.5 MDa), cylinder-shaped multimeric dimer
protease arranged as four axially stacked heptameric rings (235). Its proteolytic
active sites are situated in a cylindrical chamber, the 20S core, which has a 19S re-
gulator complex, also called PA700 or cap complexes, at either end (236). The com-
plex of one 20S and two 19S subunits form the 26S proteasome. The 20S core par-
ticle contains seven evolutionarily related, but not identical, subunits, that include
two homologous gene products, α and β (237). The two outer rings are composed
of α-subunits (α1-α7), which form the "gates" through which substrates enter and
products are released, whereas the two inner rings are composed of β-subunits (β1-
β7) (238). Three of these β-subunits, β1, β2, and β5, contain the active sites. The
catalytically active residue is a single threonine located at the amino termini of the
three β-subunits (239), and characterizes the proteasome as a member of the fami-
ly of amino-terminal nucleophile hydrolases (240, 241). Each of the three β-sub-
units has a different preference for cleavage, characterizing the proteasome with
three activities with distinct specificities against short synthetic peptides: a
"chemotryptic-like" activity with preference for tyrosine or phenylalanine at the P1
position; a "tryptic-like" activity with preference for arginine or lysine at the P1
position; and a "postglutamyl" hydrolyzing activity with a preference for glutamate
or other acidic residues at the P1 position (242, 243). 
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The 19S regulatory particle plays several roles in regulating proteasomal activity,
including substrate selection, translocation into the core particle, as well as influ-
encing the nature of products generated by the core particle. The 19S regulator has
two multisubunit components, one constitutes the base and the other the lid. The
base, composed of six ATPases of the AAA family plus two non-ATPases subunits
(244), binds to the 20S core. The ATPases function as chaperones to help unfolding
substrates and to transfer them into the 20S core, thereby controlling access of sub-
strates to the proteases within (245, 246, 247). The lid, on its turn, is composed of
eight different non-ATPase subunits with unknown function. 
The proteasome recognizes its substrates via the ubiquitin chains (248). The pro-
teasome degrades proteins into small peptides of about seven to nine amino acids,
which can, in turn, be hydrolyzed to amino acids by cytosolic peptidases. The 26S
proteasome is responsible for the degradation of abnormal and damaged proteins
(243), of oncogenes and tumor suppressors (249), of cell-cycle regulators (250,
251), in the processing of antigens (252), and in the activation or degradation of
transcription factors (253, 254). The essential function of the proteasome in these
processes was first discovered by the analysis of inactive mutants and the applica-
tion of specific inhibitors (255, 180, 256). Covalent attachment of lactacystin, a
Streptomyces cerevisiae metabolite, to the catalytically active threonine of β-sub-
units irreversibly inhibits proteolytic activity, indicating that this residue is essential
for catalysis and that lactacystin or, in fact, clasto-lactacystin β-lactone, a product
of lactacystin hydrolysis that actually reacts with the proteasome (257), can be used
as a powerful tool for proteasome inhibition (255). Other covalent inhibitors are
peptidyl vinyl sulfones (258), or dipeptidyl boronic acids (259). Reversible
inhibitors of the proteasome include peptide aldehydes (260). Most of the protea-
some inhibitors act by reacting with the threonine of the β subunits (249). 
The 26S proteasome was shown to degrade misfolded or damaged secretory pro-
teins from the ER in an ubiquitin- and ATP-dependent way in the cytosol, a mecha-
nism known as the ER-associated degradation pathway (ERAD) (261, 262). By use
of specific localization signals, the 26S proteasome can be transported to different
locations in the cytosol or nucleus, depending where his action is needed (263, 264).
Besides completely degrading most of polyubiquitinated proteins, in some cases
only partial degradation occurs. In case of the inducible transcription nuclear factor
κB (NF-κB), responsible for regulating the transcription of several cellular genes
involved in the immediate early processes of acute phase, inflammatory and
immune responses, the proteasome partially degrades the ubiquitinated C-terminal
domain form of the p105 precursor protein (265, 266). Partial processing of p105
leads to the formation of the p50 protein, which will then interact with RelA (p65)
to form an active NF-κB, which on its turn, will translocate to the nucleus to induce
its activity. Partial degradation of p105 suggests that certain amino acid sequence in
this protein, a glycine-rich region, can induce its release from the proteasome (267). 
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Ubiquitination of Membrane Proteins 
ER membrane proteins
As mentioned above, ERAD serves an important role in cellular defense and qua-
lity control by targeting abnormal/misfolded proteins, or excess of un-assembled
subunits of multi-subunit complexes, for ubiquitination and proteasome degrada-
tion. These proteins undergo a retrograde transport from the ER to the cytosol, also
termed dislocation, by using the same translocon in opposite direction (268, 269).
The protein channel mediating these transports is the translocon, composed of the
trimeric ER membrane protein Sec61, the heterodimeric signal-sequence recogni-
tion particle (SRP) receptor, and in some cases the translocating chain-associating
membrane (TRAM) protein (270). Several ER proteins have been shown to require
specific E2s and to become ubiquitinated for degradation by the proteasome, like
for instance ENaC (200), mutant sec61 (271, 272), Na.K-ATPase α subunits (273),
and apolipoprotein B (274). Among other membrane proteins degraded via ERAD
are the yeast and human 3-hydroxyl-3-methyl-coenzyme A reductase (HMGR)
(275, 276), the mutant prion protein (277), the Wilson disease Cu2+ transporter pro-
tein (278), normal and mutated CFTR (279), and MHC class I molecules targeted
for degradation by the cytomegalovirus-encoded proteins US2 and US11 (280).
Plasma membrane proteins 
Several permeases and transporters, like ENaC and yeast Gap1p, and cell-surface
receptors, are internalized and degraded in a ligand-dependent and ubiquitin-
dependent manner (164, 281, 282, 200, 201, 283, 284). In most cases, the protea-
some does not recognize these ubiquitinated proteins, suggesting that ubiquitination
functions in downregulating such proteins from the cell-surface. Ubiquitination
appears to activate the internalization and endocytic machineries that route the
internalized proteins to the vacuole/lysosome, where they are degraded. Possibly,
ligand binding to its receptor triggers either exposure of the ligase binding site(s) or
phosphorylation sites. In the latter case, phosphorylation then recruits the conjuga-
tion machinery. The mechanisms by which ubiquitin triggers internalization of
membrane proteins are still unknown. Normally, internalization is triggered by tyro-
sine- or di-leucine motifs, which interact with the clathrin adaptor protein AP-2
(285, 286), resulting in clathrin activation and coated pit formation. These clathrin-
coated buds will then pinch off from the plasma membrane and form clathrin-coat-
ed vesicles. Analogous to AP-2, ubiquitin could act as an adaptor between lysine
residues in membrane proteins and clathrin, or between amino acid sequences in the
ubiquitin molecule itself and AP-2 molecules. 
In yeast, G protein-coupled α-factor receptors, like Ste2p (281) and Ste3p (287),
and transporters, like uracil permease Fur4 (288, 289), the maltose permease Mal61
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(290), the galactose transporter Gal2p (291), and the ABC peptide transporter Ste6p
(292), are ubiquitinated upon ligand binding. Ubiquitination of these proteins marks
them for proteolysis, resulting in their internalization and degradation in the va-
cuole, the yeast equivalent of the lysosome.
Monoubiquitination of certain proteins, like Ste2p and Gal2p, has been shown to be
sufficient to trigger endocytosis, suggesting that ubiquitination of such proteins is
not involved in proteasomal degradation, since monoubiquitinated proteins are not
a target for the proteasome (183). Fur4p seems to be modified by polyubiquitin
chains, but the ubiquitin moieties are linked via Lys63, not Lys48 that is common-
ly used for ubiquitin attachment (a linkage that appears to be necessary for maximal
rates of endocytosis) (288). Since endocytosis of Fur4p requires the "destruction
box", it seems likely that ubiquitination motifs necessary for the degradation of cer-
tain proteins are also involved in endocytosis of other proteins (284). 
In mammalian cells, it was shown for the Met receptor (293) and the platelet-
derived growth factor (PDGF) receptor (294, 295) that ubiquitination might initiate
proteasome action. Ubiquitinated forms of these proteins were observed in endoso-
mal/lysosomal compartments (296, 297), suggesting that the proteasome is
involved in a partial degradation of the cytosolic tails, while the lumenal and trans-
membrane domains are degraded in the lysosome. Until now, the role of the ubi-
quitin system in endocytosis and degradation of the receptors for immunoglobulin
E (IgE) (298), CSF-1 (294), SLF (299) and the T cell antigen receptor (300), is
unclear. However, ubiquitination of ENaC and GHR is clearly involved in their
endocytosis, where ubiquitination acts as an internalization signal. Internalization
of ENaC depends on ubiquitination of its α- and  γ-subunits by the HECT domain
E3 Nedd4 (200,301), and its rapid degradation is prevented by inhibitors of both the
proteasome and lysosome (200). It was suggested that the assembled ENaC com-
plex subunits might be degraded by the lysosome, while unassembled subunits
could be degraded by the proteasome. For the GHR, it was shown that ligand-
dependent GHR endocytosis depends on an intact ubiquitin system (83, 302).
Several steps in the internalization/degradation pathway could be regulated by ubi-
quitination. In some cases, it is not the receptor, but another nonreceptor protein that
requires ubiquitination. For instance, Eps15, a protein that becomes receptor-asso-
ciated, phosphorylated, ubiquitinated, and localized to the clathrin-coated pits upon
ligand binding of the EGFR (303, 304, 305). In other cases, ubiquitination plays a
role in the endosomal sorting pathway. Some receptor ligands such as EGF, PDGF
and colony stimulating factor (CSF-1), induce the ubiquitination both of their recep-
tors and of a tyrosine kinase regulator, c-cbl (306, 307, 308). C-cbl has been shown
to participate in the endosomal sorting by binding and enhancing the ubiquitination
of the cytoplasmic domain of the endocytosed receptors (309). Such ubiquitinated
receptors are localized to the lysosome for degradation, while those that are not
ubiquitinated are recycled to the cell-surface. The precise role of the proteasome in
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this membrane sorting process is still unclear. Involvement of proteasomes in the
degradation of cytosolic tails has not been established for any of the described pro-
teins. Degradation products in the absence or presence of specific proteasome
inhibitors have not been described, not even when antibodies were directed against
the extracellular 'proteasome-undegradable' part of these cell-surface proteins. This
does not exclude proteasome action, as the proteasome might degrade the cytosolic
domains of these proteins gradually, during their transport from the plasma mem-
brane to the lysosome. This would result in degradation intermediates of different
lengths, which are not easily detectable by immunoblotting (284). 
Ubiquitin system-dependent endocytosis of the GHR
In the presence of ligand GHR endocytoses rapidly via clathrin-coated pits (310),
and its degradation occurs at least partially within the lysosome (311). The GHR
was initially found ubiquitinated upon amino acid sequencing of the receptor from
rabbit liver (11). The ubiquitin system is required for ligand-induced GHR inter-
nalization (83). In a chinese hamster cell line carrying a temperature-sensitive E1
enzyme (ts20 cells), inactivation of E1 results in accumulation of non-ubiquitina-
ted GHRs at the plasma membrane, while internalization of the transferrin receptor
is unaffected (83). In contrast to several other proteins (200, 312), ubiquitination
itself is not important for endocytosis, as substitution of all the Lys residues in the
cytosolic tail did not affect the process (313). Yet, the ubiquitin conjugation machi-
nery is still essential for endocytosis, and a 10 amino acid sequence in the tail, de-
signated ubiquitin endocytosis (UbE) motif and involved in both GHR ubiquitina-
tion and ligand-induced endocytosis (313), is required for this activity. Probably,
this motif serves, directly or via adaptor proteins, as an anchoring site for possible
E2s/E3s, leading to coated pit localization and subsequently to GHR internalization.
Upon binding of the ubiquitinating enzymes, interaction with an endocytic adaptor,
e.g. AP2 could occur, or alternatively, the E2/E3 complex could serve as an adap-
tor, analogous to the role of arrestin for the β-adrenergic receptor (314). If ubiqui-
tination of a GHR-associated protein is involved in the endocytosis process, possi-
ble candidates could be Eps15 and c-Cbl, as mentioned above.The UbE motif does
not resemble any other known ubiquitination domain (313), and mutation of the
aromatic as well as the acidic residues did not allow internalization. In particular,
the phenylalanine at position 327 mutated to an alanine blocked internalization.
Possible candidates containing an UbE motif and reported to be also ubiquitinated
are for instance, the prolactin receptor (315), the PDGF receptor (316), and the c-
erbB-2 receptor (317). 
Recently, the proteasome has been shown to also be involved in GHR downregula-
tion (318). GHR internalization requires proteasomal action in addition to an active
ubiquitin conjugation system. Specific proteasomal inhibitors block GH uptake of
the full-length GHR, while a truncated receptor can endocytose undisturbed (318).
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Furthermore, if the GHR is truncated at position 349, a latent di-leucine endocyto-
sis motif becomes active and the UbE motif is no longer required for ligand-induced
internalization (313). This suggests that upon removal of a portion of the tail, this
di-leucine motif is activated, and therefore, the GHR cytosolic tail is cut from the
C-terminus.
The ubiquitin system and the stress response
Stresses such as elevated temperatures, heavy metals, amino acid analogs, viral
infection, oxidative and chemical damage, or the production of abnormal proteins
trigger vital cellular responses, either to repair the damage, or to limit its toxicity to
the cell. Normally, transcriptional induction of a set of genes whose products,
known as stress proteins, enhances survival under stress conditions (for review:
319). The synthesis of heat shock proteins at sub-heat shock temperatures is trig-
gered by the forced production of denatured proteins (320), indicating that protein
damage is the key event in the induction of the stress response. When the ubiquitin
pathway was described as a mechanism for selective degradation of abnormal pro-
teins containing amino acid analogs (321, 322, 191), it first confirmed its important
role in stress response. Subsequently, certain components of the pathway were
found to be stress proteins, and ubiquitin conjugation was increased in heat shock
and other stress conditions. Ubiquitin itself is a stress protein, where its expression
is induced by diverse stresses, including heat shock (323), heavy metals (arsenium
and cadmium) (178), amino acid analogs (323), DNA-damaging agents (324) and
oxidants (325). Imposition of stress is usually accompanied by a dramatic redistri-
bution of ubiquitin, such that the fraction of ubiquitin that is unconjugated decrea-
ses, while the fraction of ubiquitin in conjugates increases (323, 327, 328). The
requirement of ubiquitin expression in stressed cells reflects the need to replenish
the pool of free ubiquitin, and in the absence of such replenishment, the ubiquitina-
tion of denatured proteins is inhibited and these species accumulate to toxic levels.
Expression of specific E2 enzymes is also up-regulated in stressed cells (326). In
yeast, UBC5 is important for the ubiquitination and turnover of normal-short-lived
proteins, but also in heat shock and cadmium induced stress (326, 178). No E3
enzymes have yet been identified as stress proteins, nor has any E3 been shown to
play an important role in the stress response. The effect of stress can be extreme: in
unstressed cells, about 50% of the ubiquitin is unconjugated (329), whereas less
than 10% of the ubiquitin is unconjugated in heat-shocked HeLa cells (330). The
use of protein synthesis inhibitors like cycloheximide, does not prevent stress-
induced ubiquitin redistribution, suggesting that this event is mainly due to
increased susceptibility of proteins to ubiquitination. However, up-regulation of
ubiquitin and E2s might also contribute to increased conjugate levels (328). 
Upon oxidative stress, both protein ubiquitination and proteasomal degradation
have been demonstrated (328, 331). Oxidative stress damages cells, and has been
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implicated in several processes, including degenerative diseases of aging,
Alzheimer's and Parkinson's disease, arthritis, atherosclerosis, and cancer (332, 333,
334, 335, 336, 337). The exposure of cells to high levels of oxygen free radicals
results in damage of proteins, lipids, DNA, and enzyme activity, affecting both cell
proliferation and differentiation. Proteins containing tiol groups/Cys residues are
sensitive targets of oxidants, where, for instance, phosphorylation /dephosphoryla-
tion activities are affected. Several proteins involved in signal transduction, inclu-
ding MAPKs, Raf-1, Ras, and growth factors receptors, such as EGFR and PDGFR,
are phosphorylated and activated upon oxidative stress (338, 339, 340, 341, 342). It
is thought that the increased EGFR phosphorylation upon hydrogen peroxide
(H2O2) exposure, is a result of tyrosine phosphatase inactivation (341, 343).
Following cellular exposure to oxidants, the levels of the primary cellular
sulfhydryl reductant glutathione (GSH) decrease, while the levels of its oxidized
form (GSSG) increase. Upon severe oxidative stress, ubiquitination of proteins is
also decreased, suggesting that oxidative stress interferes with E1/E2 activities
(344, 345). These enzymes contain active site sulfhydryls that might be covalently
modified (thiolated) upon enhancement of GSSG levels (glutathiolation).
Glutathiolation might regulate the levels of ubiquitinated proteins in response to
oxidative stress (345). Furthermore, the 20S proteasome was found more resistant
to oxidative stress than the ATP- and ubiquitin-dependent 26S proteasome (346).
Ubiquitin-dependent receptor endocytosis is also affected by oxidative stress. Both
internalization of N-acetlyglucosamine-specific chicken hepatic lectin (CHL)
receptor (347), and EGFR (348) were shown to become inhibited upon H2O2 stress.
Possibly, H2O2 inhibits EGFR internalization by inhibition of Eps15 ubiquitination,
known to be involved in the internalization process (348). Whether GHR constitu-
tive levels at the plasma membrane are also affected by stress-induced ubiquitina-
tion, is a question to be answered.
Scope of this thesis
The ubiquitin-proteasome system is known to be involved in GHR endocytosis,
where an active ubiquitin system is necessary for receptor ubiquitination and its
consequent internalization. Endocytosis of the GHR has also been shown to be re-
gulated by the proteasome. This thesis focuses, first of all, on the effect of the ubi-
quitin system on the GHR signal transduction and downregulation. In chapter 2, we
studied the role of the ubiquitin system in the signal transduction of the GHR. By
using specific proteasome inhibitors, we determined their effect on GH-induced
activity of both GHR and JAK2 in both the wild-type GHR and in the internaliza-
tion-deficient GHR mutant F327A. We suggest possible models for the role of the
ubiquitin-proteasome system in GHR signal transduction. Furthermore, we asked
the question involving the continuation of signal transduction of the GHR after its
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internalization, where binding of JAK2 as well as other activated proteins to the
GHR, not only at the cell-surface but also intracellularly, was determined.
Degradation products of the GHR were determined in both cell-surface and in endo-
somes, indicating that part of the receptor is down-regulated by the proteasome.
In chapter 3, we focused on the role of JAK2-mediated signal transduction in GHR
internalization and downregulation. Using a box-1 mutant of the GHR, activation
of both GHR and JAK2 was determined, as well as receptor-bound GH internaliza-
tion and GHR turnover and transport to the plasma membrane. We determined the
role of GHR signal transduction, via JAK2, on GHR ubiquitination, endocytosis
and degradation, and the role of the ubiquitin system on the regulation of both GHR
internalization and signal transduction.
Finally, chapter 4 discusses the role of stress in regulating GHR levels in the cell.
We determined the effect of H2O2 on receptor's turnover and on receptor's down-
regulation from the cell-surface. We further determined the effect of oxidative stress
on the amount of ligand binding sites at the cell-surface and related these results
with the enhancement of shedding activity directed to the GHR.
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Abstract
The growth hormone receptor (GHR) intracellular domain contains all of the infor-
mation required for signal transduction as well as for endocytosis. Previously, we
showed that the proteasome mediates the clathrin-mediated endocytosis of the
GHR. Here we present evidence that the proteasomal inhibitor MG132 prolongs the
GH-induced activity of both GHR and JAK2, presumably through stabilization of
GHR and JAK2 tyrosine phosphorylation. If proteasomal inhibitor was combined
with ligand in an endocytosis-deficient GHR mutant, the same phenomena occurred
indicating that proteasomal action on tyrosine dephosphorylation is independent of
endocytosis. Experiments with a GHR truncated tail mutant (GHR1-369) led to a
prolonged JAK2 phosphorylation due to the loss of a phosphatase-binding site. This
raised the question of what happens to the signal transduction of the GHR after its
internalization. Co-immunoprecipitation of GH-GHR complexes before and after
endocytosis showed that JAK2 as well as other activated proteins are bound to the
GHR not only at the cell-surface but also intracellularly, suggesting that the GHR
signal transduction continues in endosomes. Additionally, these results provide evi-
dence that GHR is present in endosomes both in its full-length and truncated form,
indicating that the receptor is downregulated by the proteasome.
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Introduction 
The growth hormone receptor (GHR) is a member of the cytokine/hematopoietin
receptor superfamily (for review see 1). Cytokines regulate different aspects of cel-
lular growth, differentiation and activation and play a critical role in immune and
inflammatory responses. In response to GH, two GHR polypeptides dimerize, turn-
ing on a cascade of events leading to signal transduction by activating gene trans-
cription in the cell nucleus and, at the same time, downregulation and degradation
of the receptor (2, 3).
One major characteristic of the cytokine receptor family is the absence of an intrin-
sic tyrosine kinase activity. Upon dimerization, the GHR recruits and activates
JAK2, a member of the Janus family of cytosolic kinases (4-6). Once bound, the
two JAK2 molecules are in opposition and can transphosphorylate each other.
Subsequently, the receptor chains become tyrosine phosphorylated allowing them to
interact with other intracellular signaling components (6). JAK2 acts via special sig-
nal transducers and activators of transcription proteins (STATs), which dimerize and
translocate to the nucleus to convey the appropriate signal to specific regulatory
DNA-response elements (7, 8). In addition, JAK2 activation by GH facilitates ini-
tiation of various pathways including the Ras, mitogen-activated protein kinase
(MAPK), the insulin receptor substrate (IRS) and the phosphatidylinositol 3-kinase
(PI-3K) pathway (9, 10). GH-induced activation of the JAK/STAT signal transduc-
tion pathway is both rapid and transient. The molecular mechanism of JAK deacti-
vation is still poorly understood. Part of the dephosphorylation of the GHR has been
previously attributed to the activation of the tyrosine phosphatase SHP-1 (11). This
enzyme was found to interact with JAK2 and GH stimulates the catalytic activity of
SHP-1 (11). Another candidate could be SHP-2 since it associates with the GHR,
and binding to JAK2 has also been reported. However, no dephosphorylation of
JAK2 by SHP-2 could be demonstrated (12). Recently, another negative regulatory
pathway of the GH receptor signaling involving the SOCS (suppressor of cytokine
signaling) proteins has been identified (13, 14). The SOCS proteins appear to form
part of a negative feedback loop that regulates cytokine signal transduction. Their
expression is rapidly induced by activation of the JAK/STAT pathway (15).
Another important system which downregulates the GHR is the ubiquitin-protea-
some system. This system regulates the degradation of nuclear and cytosolic pro-
teins via the proteasome (16). The target proteins are first tagged with ubiquitin
molecules to form a polyubiquitin chain, which is specifically recognized by the
multi-subunit proteasome complex, leading to their degradation. Proteasomes were
found to be involved in regulating JAK/STAT pathways upon interleukin-2, -3 and
erythropoietin stimulation (17-19). In the presence of specific proteasomal
inhibitors, activation of both JAK and STAT molecules was sustained, although nei-
ther STAT nor JAK appeared to be ubiquitinated. These data indicate that protea-
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somes are involved in the downregulation of the activation signals of specific
cytokine receptors.
An important factor in GHR down-regulation is its endocytosis. In the presence of
ligand GHR endocytoses rapidly via clathrin-coated pits (20), and its degradation
occurs at least partially within the lysosome (21). The ubiquitin system is required
for ligand-induced GHR internalization (14). In particular, the UbE motif within the
GHR cytosolic tail is involved in both GHR ubiquitination and ligand-induced
endocytosis (22). In a chinese hamster cell line carrying a temperature-sensitive E1
enzyme (ts20 cells), inactivation of E1 results in accumulation of non-ubiquitina-
ted GHRs at the plasma membrane, while internalization of the transferrin receptor
is unaffected (23). Recently, we showed that the proteasome is also involved in
GHR downregulation (24). GHR internalization requires proteasomal action in
addition to an active ubiquitin conjugation system. Specific proteasomal inhibitors
block GH uptake of the full-length GHR, while a truncated receptor can endocytose
undisturbed.
In this report, we address the role of proteasome-mediated protein degradation in
modulating GHR/JAK2 activity following GH stimulation. We show that the pro-
teasomal inhibitor MG132 prolongs the GH-induced activity of both GHR and
JAK2, presumably through stabilization of GHR and JAK2 tyrosine phosphoryla-
tion. Furthermore, we observe that JAK2 is not only bound to the GHR at the cell-
surface but also intracellularly, suggesting that the receptor and other signal trans-
ducing molecules are still active in endosomes. 
Experimental procedures
Cells and Materials
Chinese hamster ts20 cells were stably transfected as described previously (23).
Truncated receptors were constructed by introducing stop codons at various posi-
tions within the rabbit cDNA (25). These truncated GHR cDNAs were cloned in
pcDNA3 (In Vitrogene Inc.) and transfected into ts20 cells, resulting in cell lines
stably expressing receptors truncated at amino-acid residues 399 and 369. The inter-
nalization-deficient mutant GHR F327A was constructed by site-directed mutage-
nesis, cloned and transfected into ts20 cells as described before (25). Stable,
geneticin-resistant transfectants were grown in Eagle's minimal essential medium
(MEM-α) supplemented with 10% fetal bovine serum, penicillin and streptomycin,
4.5 g/liter glucose, and 0.45 mg/ml geneticin. For experiments, cells were grown in
the absence of geneticin at approximately 70% confluence.
Antibody to GHR was raised against amino acids 271-381 of the cytoplasmic tail
(anti-GHR(T)) as previously described (23). Antibody (Mab5) recognizing the
lumenal part of the GHR was from AGEN Inc., Parsippany, NJ. Antiserum against
JAK2 was raised in rabbits against a synthetic peptide corresponding to the hinge
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region (amino acids 758-777) between domains 1 and 2 of murine JAK2.
Polyclonal antibody against JAK2 and phosphotyrosine (4G10, anti-PY) were
obtained from Upstate Bio-technologies Inc. (Lake Placid, NY). Antiserum against
human GH was raised in rabbits. Commercial anti-GH was from DAKOPATTS.
hGH was a gift of Lilly Research Labs, Indianapolis, IN. Culture medium, fetal calf
serum (FCS) and geneticin were purchased from Gibco. MG132 was from
CalBiochem.
Cell lysis, immunoprecipitation and immunoblotting
Cells, grown in 10-cm dishes, were first incubated for 2 hours at 30°C in FCS-free
MEM-α- in presence or absence of 20 mM MG132. After hGH (8 nM) incubation,
cells were lysed on ice in 0.6 ml of lysis mix containing 1% Triton X-100, 1 mM
EDTA, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 mM phenylmethylsulfonyl fluo-
ride, 1 mM Na3VO4 and 50 mM NaF in PBS. The immunoprecipitations were per-
formed in 1% Triton X-100, 0.5% SDS, 0.25% sodium deoxycholate, 0.5% bovine
serum albumin, 1 mM EDTA, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 mM
phenylmethylsulfonyl fluoride, 1 mM Na3VO4 and 50 mM NaF in PBS. The
lysates were cleared by centrifugation and incubated with GHR antiserum or JAK2
antiserum for 2 hours on ice. Protein A-agarose beads (Repligen Co., Cambridge,
MA) were used to isolate the immune complexes. The immunoprecipitates were
washed twice with the same buffer and twice with 10-fold diluted PBS. Immune
complexes were analyzed by poly-acrylamide gel electrophoresis in the presence of
SDS (SDS-PAGE) together with total cellular lysate and transferred to polyvinyli-
dene difluoride paper. The blots were immunostained using either Mab 4G10 (anti-
PY), anti-GHR or commercial JAK2 antibody. After incubating the blots with rab-
bit anti-mouse IgG (RAMPO) or protein A conjugated to HRP, antigens were visua-
lized using the ECL system (Boehringer Mannheim).
Co-immunoprecipitation of internalized proteins
Cells, grown on 10-cm dishes, were incubated 1 hour on ice in MEM-a, supple-
mented with 20 mM Hepes, and with 8 nM hGH. The cells were then washed once
to remove unbound GH and incubated at 30°C for different periods of time. Cells
were put on ice after which the cell- surface labeled GH was removed by two times
30 sec with acidic solution of 50 mM glycine, 150 mM NaCl pH 2.5. The cells were
washed with PBS and lysed in 0.1% Triton X-100, 1 mM EDTA, 0.5% BSA, 10
mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 1 mM
Na3VO4 and 50 mM NaF in PBS. Immunoprecipitations were performed in the
same buffer with GH antiserum for 2 hours on ice. The immune complexes were
treated as above. The blots were immunostained using Mab 4G10 or JAK2 anti-
body.
For the acid wash control, a competition assay was performed by using unstimula-
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ted lysates of GHR 1-369 to lyse GH-stimulated wtGHR cells that were treated as
described above.
Results
Effect of specific proteasomal inhibitors on GHR phosphorylation
To determine whether the proteasome is involved in modulating GHR activity, we
examined the effects of the proteasomal inhibitor MG132 on GH-induced GHR
phosphorylation. Using ts20 cells stably transfected with wtGHR, the time course
of tyrosine phosphorylation of the GHR was determined following GH stimulation
in the presence and absence of MG132 (Fig. 1). In the absence of GH, no phospho-
rylated GHR was visible (Fig. 1A). Upon GH stimulation a broad 130-kDa band
appeared, indicating the GHR tyrosine phosphorylation. The activity was maximal
within 15 min and decreased thereafter. If MG132 was present, virtually no
decrease of the GHR phosphorylation signal was observed even after two hours.
Reblotting with an anti-GHR antibody showed equivalent amounts of total
immunoreactive protein in all samples, indicating that MG132 had little effect on
the steady-state level of the GHR (Fig. 1B). Since GH stimulation was continuous,
it was not possible to discriminate the population of down-regulated receptors from
newly synthesized receptors as done previously by a metabolically labeled pulse-
chase experiment (24). Thus, prolonged phosphorylation of the receptor due to the
presence of MG132 could account for the sustained presence of the receptor at the
cell-surface.
A
B
wt GHR GHR F327A
IP: anti-GHR (T)
Blot: anti-PY
IP: anti-GHR (T)
Blot: anti-GHR (T)
GH: 0 15 60 120 0 15 60 120 0 15 60 120 180 0 15 60 120 180 min
GH: 0 15 60 120 0 15 60 120 0 15 60 120 180 0 15 60 120 180 min
D
C
Control + MG132 Control + MG132
Control + MG132 Control + MG132
mGHR
mGHR
pGHR
Fig. 1. Effect of MG132 on GHR
phosphorylation. Cells were incubat-
ed for 2 hours at 30°C without (control)
or with 20 mM MG132 and supple-
mented with 8 nM hGH for the time
periods indicated. Cell lysates were
prepared and subjected to immunopre-
cipitation (IP) of the GHR by using
anti-GHR(T) and subjected to immu-
noblot analysis with an antibody
against phosphotyrosine residues (anti-
PY). A, ts20 cells expressing the
wtGHR. C, ts20 cells expressing the
GHR F327A. B and D, the PY blots
were reblotted with anti-GHR(T).
Arrows indicate mature (mGHR) and
precursor (pGHR) forms of the GHR.
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The MG132 effect is not due to inhibition of internalization of GHR
Our previous results have shown that MG132 prevents internalization of the GHR
(24). It is anticipated that a prolonged stay at the cell-surface might result in a pro-
longed phosphorylated state of the GHR and of JAK2. To test this, we used the
GHR F327A transfected cells, which express receptors defective in internalization
(25, 26). The kinetics of tyrosine phosphorylation/dephosphorylation of the GHR
F327A were similar to the wtGHR (Fig. 1C), reaching a maximum after 15 min and
decreasing to basal levels after 2 hours of GH treatment. However, in the presence
of MG132, the level of tyrosine phosphorylation of the GHR F327A remained the
same. Thus, down-regulation of the GHR phosphorylation depends on proteasomal
action, and is not related to the GH-induced endocytosis.
GHR sustained activation is due to prolonged JAK2 phosphorylation
Proteasomal inhibitors prolong signaling of the interferon-gamma receptors after
ligand stimulation, showing sustained tyrosine phosphorylation of both the recep-
tors and JAK1/JAK3 (17). To determine whether the effect of MG132 on GHR
phosphorylation is due to sustained activation of JAK2 kinase, anti-JAK2 immuno-
precipitates were prepared from cell lysates and analyzed by immunoblotting with
an antibody to phosphotyrosine. As shown in Fig. 2A, GH induced a transient phos-
phorylation of JAK2 with a maximum at 15 min in the absence of proteasomal
inhibitor, declining to nearly basal levels after 2 hours. However, treatment of the
cells with MG132 prevented the dephosphorylation of JAK2, correlating well with
the sustained GHR activity (compare lanes 4 and 8). Reblotting with an anti-JAK2
antibody showed similar amounts of immunoreactive protein in all samples indi-
cating that MG132 had little effect on the stability of the protein (Fig. 2B). Shorter
B
A
D
C
IP: anti-JAK2
Blot: anti-PY
IP: anti-JAK2
Blot: anti-JAK2
wt GHR GHR F327A
Control + MG132 Control + MG132
Control + MG132 Control + MG132
GH: 0 15 60 120 0 15 60 120 0 15 60 120 0 15 60 120 min
GH: 0 15 60 120 0 15 60 120 0 15 60 120 0 15 60 120 min
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
JAK2
JAK2
Fig. 2. Effect of MG132 on JAK2 phos-
phorylation. The procedure was as in
Fig. 1, except that anti-JAK2 immuno-
precipitations were subjected to an anti-
PY immunoblot analysis. A, ts20 cells
expressing the wtGHR. C, ts20 cells
expressing the GHR F327A. In B and D,
the resulting immunoprecipitates were
reblotted with anti-JAK2.
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preincubation periods with MG132 were as effective in stabilizing the tyrosine
phosphorylation of JAK2, suggesting that its mechanism of action is specific and
not due to general cell toxic effects. The same was observed for the GHR F327A
mutant (Fig. 2C and 2D). JAK2 activation was transient in this mutant, but as for
the wtGHR, MG132 treatment prolonged JAK2 phosphorylation in a similar way.
Taken together, these results demonstrate that MG132 prolongs the GH-induced
activity of both GHR and JAK2, presumably through stabilization of GHR and
JAK2 tyrosine phosphorylation. Thus, the proteasome plays a role in decreasing
GHR signal transduction.
Possible role of proteasomes in modulating phosphatase activity
Previous reports have implicated JAK proteins in dephosphorylation by interaction
with specific phosphatases (12,27-29). Hackett et al., using FDP-C1 cells, demons-
trated that the region in the GHR cytosolic tail between 521 and 540 is required for
inactivation of the JAK/STAT signaling cascade, possibly via the protein tyrosine
phosphatase SHP-1 that acts as a negative regulator (11). However, SHP-1 does not
seem to associate with the GHR. Also the tyrosine phosphatase SHP-2, another
member of the protein-tyrosine phosphatase family that, unlike SHP-1, is ubiqui-
tously expressed in vertebrate cells, was shown to form a complex with both the
tyrosine phosphorylated receptor (GHR cytoplasmic domain residues 485-620) and
JAK2 protein (30). We determined whether MG132 would also induce prolonged
JAK2 phosphorylation upon GH treatment in a C-terminally truncated GHR. JAK2
was immunoprecipitated from GHR 1-399 and GHR 1-369 expressing cells and
immunoblotted with antiphosphotyrosine antibodies for various times of GH treat-
ment (Fig. 3A and C). In both cell lines, JAK2 showed tyrosine phosphorylation
with no change during time. In accordance with the above-mentioned studies,
IP: anti-JAK2
Blot: anti-JAK2
IP: anti-JAK2
Blot: anti-PY
GHR 1-399 GHR 1-369
B
A
D
C
GH: 0 15 60 120 0 15 60 120 0 15 60 120 0 15 60 120 min
GH: 0 15 60 120 0 15 60 120 0 15 60 120 0 15 60 120 min
Control + MG132 Control + MG132
Control + MG132 Control + MG132
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
JAK2
JAK2
Fig. 3. Effect of MG132 on JAK2
phosphorylation in truncated
GHR?expressing cells. Ts20 cells
expressing GHR 1-399 (A) or
GHR 1-369 (C) were incubated at
30°C without (control) or with 20
mM MG132 and supplemented
with 8 nM hGH for the time peri-
ods indicated. The truncated forms
of the GHR were immunoprecipi-
tated with anti-GHR(T) and
immunoblotted with anti-PY.
Reblots with anti-GHR(T) are
shown on B and D.
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delayed dephosphorylation of the kinase was observed both in the presence and
absence of MG132. Reprobing the blots with JAK2 antibody confirmed the pre-
sence of equal amounts of JAK2 protein in each sample (Fig. 3B and 3D). These
results suggest that the activation of a negative regulator (SHP-1 or SHP-2) through
distal GHR tail domains and further association with JAK2 might be the important
factor responsible for down-regulating the GHR/JAK2 phosphorylation in a protea-
some-dependent way. Thus, inhibition of the proteasome by MG132 inhibits the
dephosphorylation of JAK2, resulting in prolonged activity of both JAK2 and GHR.
However, MG132 had no effect on SHP-2 phosphorylation upon GH induction, or
had any effect on SHP-2 binding to both GHR and JAK2 (results not shown).
As shown previously, proteasomal inhibitors do not affect internalization of GH via
the GHR 1-369 but effectively block endocytosis of GHR 1-399 (24). As JAK2
phosphorylation is similar in both cell lines, the data implicate that signaling might
continue after endocytosis.
JAK2 protein is bound to GHR in endosomes
Signaling via the GHR begins at the cell-surface. As demonstrated above using the
endocytosis-defective GHR F327A cell line, the activation/deactivation (tyrosine
phosphorylation/ dephosphorylation) cycle can be initiated and completed at the
GH: min0 15 30 60 - 0 15 30 60 0 10 15 60 0 10 15 60
wt GHR GHR 1-369A B
IP: anti-GH
Blot: anti-GHR (Mab5)
Acid
Wash: - - - - + + + + - - - - + + + +
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
mGHR
mGHR
GH: min0 15 30 60 015 30 60 0 0 0 10 15 60 0 10 15 60
IP: anti-GH
Blot: anti-GHR (Mab5)
IP: anti-GH
Blot: anti-GHR ( C )
Acid
Wash: - - - - + + + + - + - - - - + + + +
mGHR
wt GHR ts20 GHR F327A
mGHR
C D
Fig. 4. Acid-resistent GH-
GHR complexes are found in
the cell. A, cells expressing full
length wtGHR, B, GHR 1-369,
and D, GHR F327A were incu-
bated with 8 nM hGH on ice for
1 hour, followed by incubation
at 30°C for the time periods
indicated. The cells were then
subjected or not to an acid wash
procedure. The cell lysates
were immunoprecipitated with
ant-GH and blotted with anti-
GHR (Mab5) or as in C, with
anti-GHR (C) for cells express-
ing wtGHR.
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cell-surface. The next question is whether signal transduction can continue after
endocytosis. To address this, the activity of GHR has to be established after endo-
cytosis. To accomplish this, we isolated GH-GHR complexes using anti-GH
immunoprecipitation after acid treatment (Fig. 4). Dissociation of GH-GHR com-
plexes does not occur at (endosomal) pH 5.5 (20). This indicates that GH remains
complexed to its receptor, independent of its intracellular routing, unless it is loca-
lized to the lysosome. In that case, the ligand as well as the receptor is rapidly
degraded (21). Treating living cells with buffers of pH higher than 2.5 showed that
GH was not removed from GHR at the cell-surface, and only upon treatment with
a buffer pH 2.5 did GH detach from the receptor, without interfering with the
already internalized GH-GHR (results not shown). If no acidic treatment was per-
formed, the total amount of wtGHR bound to GH co-immunoprecipitated during the
different periods of time (Fig. 4A, lanes 1-4). The same was observed for the trun-
cated GHR 1-369 (Fig. 4B, lanes 9-12) and GHR F327A (Fig. 4D, lanes 26-29). If
the cells were kept on ice, acid treatment removed virtually all the GH from the cell-
surface and hardly any GHR was detectable (Fig. 4, lanes 5, 13, 21 and 30). Upon
incubation at 30°C, GH became acid-resistant indicating that GH-GHR complexes
had entered the cells. Within 15 min, both wtGHR and GHR 1-369 were detectable
inside the cells. Longer periods of GH treatment resulted in a decrease of GH-bound
GH: 0 0 0 15 min
GH: 0 0 0 15 min
ts20 wtGHR ts20
ts20 wtGHR ts20
Acid
wash: + - + + + + + + +
Acid
wash: + - + + + + + + +
GHR 1-369 ts20
GHR 1-369 ts20
IP: anti-GH
Blot: anti-GHR (Mab5)
DL
Blot: anti-GHR (Mab5)
mGHR
mGHR
85 kDa
85 kDa
Times excess: 1 2 3 2
Times excess: 1 2 3 2
A
B
Fig. 5. Acid-treatment control. A, cells express-
ing wtGHR were treated with GH for 15 min and
acid washed as previously, but lysis was per-
formed in presence of cell extracts from unstimu-
lated GHR 1-369 cells at 1, 2, or 3-fold excess
concentrations of wtGHRs. The cell lysates were
immunoprecipitated with anti-GH and blotted
with anti-GHR (Mab5). B, total lysates were blot-
ted with anti-GHR (Mab5).
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internalized receptors in the endosomes (lanes 8 and 16). The GHR F327A was not
observed inside the cells since internalization of this receptor is inhibited (lanes 30-
33). In addition to the 130 kDa band of the GHR, a smear of bands (60-80 kDa)
appeared which only reacted with Mab5 (Fig. 4A) and anti-GHR(T) (not shown)
and not with anti-GHR C-terminal tail antibody (Fig. 4C). No degradation products
were visible if GHR 1-369 was analyzed (not shown). These observations show that
the partial degradation of the wtGHR starts from the C-terminus very soon after GH
binding.
To exclude the possibility that during or after lysis GH is free to rebind endocytosed
or cell-surface receptor, the same experiment for wtGHR was performed but excess
of unstimulated GHR 1-369 lysate was added during lysis (Fig. 5). If free GH is
available to react with wtGHR at the cell-surface or in endosomes, then an excess
of GHR 1-369 will compete for binding to free GH. If this would be the case, then
GH immunoprecipitates blotted with anti-GHR (Mab5) should present GH com-
plexes with both wtGHR and GHR 1-369. As these receptors have different sizes
but the same GH binding affinity, they can easily be distinguished by immunoblot.
As observed on Fig. 5A, wtGHR cells were treated with GH for 15 min and acid
treated. Addition of non-stimulated GHR 1-369 lysate in different concentrations,
did not result in GH complexes containing the truncated receptor. Addition of
excess of lysate of untransfected ts20 cells to the wtGHR expressing cells was also
tested, with the same result. Fig. 5B shows total cell lysates blotted with anti-GHR
(Mab5), indicating the amount of the truncated GHR 1-369 in the incubations.
Performing the same experiment by lysing GH-treated GHR 1-369 cells in the pre-
sence of unstimulated wtGHR lysate, no GH-wtGHR complexes were detected (not
shown). 
We then addressed the question whether internalized GHR is able to bind JAK2.
The same time course experiment was performed as in Fig. 4 and analyzed for
JAK2 molecules (Fig. 6A). To measure the total amount of JAK2 bound to the GH-
GHR complex, no acidification was performed (lanes 1-3). In wtGHR transfected
cells upon acid wash, JAK2 co-immunoprecipitated with GH-GHR complexes after
internalization (lanes 5 and 6). The same was observed in the GHR 1-369 mutant
(lanes 7-9). A faster migrating background band reacted with anti-JAK2 after cell
acidification, presumably due to proteolysis. As expected, the GHR F327A mutant
did not show JAK2 binding after acidification. JAK2 was neither detectable in the
anti-GH immunoprecipitates from untransfected ts20 cells (lane 13) nor unstimu-
lated cells expressing the wtGHR, the GHR 1-369, and the GHR F327A (lanes 1, 4,
7 and 10), indicating the efficiency of the acid wash procedure. Similar amounts of
JAK2 were found for the different cell lines as seen in Fig. 6B. These results show
that JAK2 is bound to the GHR inside the cell, suggesting that the receptor is capa-
ble of signaling in endosomes.
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GHR signaling continues inside the cell 
To determine if other proteins attached to the GH-GHR in endosomes are phospho-
rylated, cells expressing wtGHR and GHR 1-369 were treated as described above
and analyzed for phosphotyrosine positive proteins. As seen in Fig. 7A, GH induced 
the phosphorylation of a set of high molecular weight proteins. Upon GH removal
from the cell-surface, the same set of proteins in the higher molecular weight range,
attached to the internalized GH-GHR complex, were phosphorylated. Untransfected
ts20 cells only resulted in a background pattern. In this molecular weight range both
wtGHR and JAK2 proteins are possible candidates, consistent with the results pre-
sented above. Surprisingly, both wild type and truncated GHR 1-369 presented si-
milar pattern of phosphorylated proteins. This can be explained by the fact that sig-
naling proteins mainly interact with the membrane proximal region of the cytosolic
tail of the GHR via JAK2. Although mainly high molecular weight proteins were
phosphorylated, we cannot exclude that also lower molecular weight proteins were
activated since the immunoprecipitation might be ineffective or the amount of mo-
lecules insufficient to allow their detection. Similar amounts of the receptor were
found in each lane as observed in Fig. 7B.
Discussion
The ubiquitin-proteasome system plays an essential role in many cellular regulato-
ry processes including cell cycle progression, DNA repair, transcriptional control
and cell-surface-associated receptor endocytosis. In all these processes the ubiqui-
tin-conjugating system targets ubiquitinated proteins to the proteasome for degra-
Fig. 6. Acid-resistent GH-GHR
complexes contain JAK2. A,
immunoprecipitates of GH-GHR
complexes were blotted for anti-
JAK2 for wtGHR, GHR 1-369,
GHR F327A and ts20 untransfected
cell lines. In B, the direct lysates
were blotted for anti-JAK2 in the
different cell lines as indicated.
GH: 0 15 30 0 15 30 0 10 15 0 15 30 0 min
GH: 0 15 30 0 15 30 0 10 15 0 15 30 0 min
GHR GHR
wt GHR 1-369 F327A ts20
GHR GHR
wt GHR 1-369 F327A ts20
A
B
IP: anti-GH
Blot: anti-JAK2
DL
Blot: anti-JAK2
Acid
wash: - - - + + + + + + + + + +
Acid
wash: - - - + + + + + + + + + +
1 2 3 4 5 6 7 8 9 10 11 12 13
JAK2
JAK2
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dation. For the GHR, the ubiquitin system was found to be involved in GH-depend-
ent endocytosis (31, for review see 32). In the present study, we demonstrate that
the ubiquitin-proteasome system is involved in the down-regulation of GHR signal
transducing events. Others have demonstrated that in several cytokine receptors the
JAK/STAT pathway was downregulated by the proteasome. Both interleukin-2 and
-3 and interferon receptor showed a prolonged JAK/STAT activation as well as
other signaling molecules like MAP kinases, upon treatment with specific protea-
somal inhibitors (18, 17). The studies described in this paper demonstrate a similar
effect for the GHR. Using ts20 cells stably transfected with wtGHR, we show that,
in the presence of the specific proteasomal inhibitor MG132, the phosphoryla-
tion/activation of both receptor and tyrosine kinase JAK2 are prolonged for long
periods of GH induction. Furthermore, our data indicate that proteasomal action on
signal transduction occurs at the cell-surface since signaling by the GHR F327A
endocytosis-deficient mutant still depends on the proteasome for its down-regula-
tion. These results support the notion that GHR/JAK2 signal down-regulation is not
determined by endocytosis per se. 
Which mechanisms underlie the down-regulation of the GHR and JAK2 proteins?
Several reports have shown that tyrosine phosphatases are involved in the dephos-
phorylation of JAK proteins. Ligand-induced tyrosine phosphorylation/activation
of JAK2 by eythropoietin receptor, induces binding of the protein tyrosine phos-
GH: min0 15 30 60 0 15 30 60 0 10 1560 0 10 15 60
GH: min0 15 30 60 0 15 30 60 0 10 15 60 0 10 15 60
wt GHR GHR 1-369
wt GHR GHR 1-369
61
85
118
187
A
B
IP: anti-GH
Blot: anti-PY
IP: anti-GH
Blot: anti-GHR (Mab5)
Acid
wash: - - - - + + + + - - - - + + + +
Acid
wash: - - - - + + + + - - - - + + + +
mGHR
61
85
118
187
Fig. 7. Phosphorylation of proteins
attached via the GH-GHR complex
after internalization. The same procedure
as in Fig 4. Immunoprecipi-tates of GH-
GHR complexes from wtGHR, GHR 1-
369 and untransfected ts20 cells were blot-
ted with anti-PY, and control blots of direct
lysates were immunoblotted with anti-
GHR(T), as shown respectively in A and
B.
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phatase SHP-1 to the cytoplasmic domain of the receptor. The recruitment of SHP-
1 is accompanied by dephosphorylation of JAK2 and subsequent termination of
eythropoietin-induced cellular proliferation (33, 34). A similar role for SHP-1 in
mediating the down-regulation of JAK2 following stimulation of cells with GH has
been proposed (11). Our results with GHR 1-399 and GHR 1-369 indicate that par-
tial deletion of the C-terminal GHR tail leads to a prolonged JAK2 phosphorylation
presumably due to loss of a negative regulator binding site and its consequent acti-
vation. This pattern of prolonged phosphorylation is similar to that of JAK2 in full
length wtGHRs treated with MG132. One explanation might be that the phos-
phatase activity is modulated by proteasome function, perhaps by degrading an
inhibiting complex in a similar manner as it occurs for the inhibitor of the trans-
cription factor NF-κB (35). This would explain why in the presence of MG132,
phosphatase inhibitors prevent dephosphorylation of the JAK2 by SHP-1, and
thereby prolonging phosphorylation of both JAK2 and the GHR. In support of this
model, SHP-1 degradation has been shown to be ubiquitin-dependent in mast cells
(36), suggesting that the proteasome is involved in SHP-1 regulation. SHP-2, how-
ever, has been shown to interact directly with the tail of the GHR (residues 484-620)
and associate with JAK2 and SIRPα1, a member of a family of transmembrane gly-
coproteins identified by its association to SH2 domain-containing SHP-2. In
response to GH, JAK2 associates with SIRPα1 and rapidly stimulates tyrosine
phosphorylation of both SIRPα1 and SHP-2, and enhances association of these two
molecules (37). Recently, it was shown that SIRPα1 is acting as a negative regula-
tor of GH signaling by its ability to bind SHP-2 (38). The proteasome could there-
fore play a role in SHP-2/SIRPα1 association and binding to JAK2. As SHP-2 is
known to associate to other signaling molecules as IRS-1 (39) and p85-PI 3-K (40),
future studies will indicate whether the MG132 effect on these molecules is direc-
tly related to SHP-2 activity. However, it cannot be excluded that activated JAK
kinases themselves are subject to proteasome-mediated degradation. Support for
this comes from a recent identified negative regulatory pathway of the GHR sig-
naling involving the SOCS proteins. GH preferentially induces the rapid, transient
expression of SOCS-3, a member of the SOCS family that is known to inhibit
cytokine receptor signaling. Expression of other SOCS genes, SOCS-1, SOCS-2
and CIS, was also up-regulated by GH, although to a lesser extent than SOCS-3 and
with different kinetics (14). Recently, it was shown that the highly conserved C-ter-
minal homology domain of the SOCS proteins, termed the SOCS box, mediates
interactions with elongins B and C, which in turn may couple SOCS proteins and
their substrates to the proteasomal protein degradation pathway (41). How SOCS
proteins inhibit JAK kinase activity is still not clear, but analogous to the family of
F-box-containing proteins, SOCS box interaction with elongins B and C potentiates
interaction with the proteasome complex. This would explain why, in presence of
MG132, degradation of SOCS proteins and its associated proteins like JAK2 would
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be prevented, and therefore induce sustained activation of JAK2 and, consequently
the GHR. Evidence for a role of the ubiquitin-proteasome system in signal trans-
duction came from experiments of Verdier and co-workers who showed that a Cis
member of the SOCS family was ubiquitinated upon erythropoietin receptor acti-
vation (19). Thus, at least two mechanisms for the termination of the GHR phos-
phorylation might depend on proteolysis: the regulation of phosphatases and of the
SOCS proteins.
Until now there is clear evidence that tyrosine kinase receptors, like the epidermal
growth factor and the insulin receptor, continue to signal after endocytosis (42, 43).
Our data with the GHR show that initiation as well as termination of its phospho-
rylation as well as of JAK2 can occur at the cell-surface. No evidence is available
about signal transduction inside the cells. Combining an acid wash procedure with
anti-GH immunoprecipitation we show that the GHR can induce a second round of
signal transduction intracellularly. This is not unexpected because obviously GH
keeps the two GHRs complexed after endocytosis. In this configuration JAK2 has
high affinity for the complex and will either rebind (if it was removed during pas-
sage of the coated pits) or will keep its position on the dimerized tails once inter-
nalized. Although the amount of undegraded, endocytosed wtGHR is very small,
the western blot signal of JAK2 complexed to the GH-GHR complexes is signifi-
cant as compared to control (non acid-washed) cells. This indicates that the signal-
ing capacity of GH-GHR complexes in endosomes is significant. The relevance for
signal transduction in endosomes is not clear. It is possible that the signaling GHR
complexes in endosomes differ from those at the cell-surface. This is not obvious
from our data, because the SDS-PAGE patterns of phosphotyrosine-containing pro-
teins of total and endocytosed GH complexes look very similar. Together, these
observations indicate that GHR signal transduction continues or resumes after
endocytosis and that the signals, regenerated at the two cellular locations, do not
substantially differ.
Another point of discussion is the presence of truncated GHR originating from the
wtGHR, not from the truncated GHR 1-369. Firstly, it is not clear where this
process starts. Experiments with the GHR F327A show that it is ubiquitin system
(UbE motif) independent, because it also occurs in this mutant GHR, and in pre-
sence of proteasome inhibitors its formation can still occur (unpublished results).
Thus, the GHR is C-terminally truncated already at the cell-surface and the trun-
cated GHR can endocytose, complexed to GH. It remains to be determined, whether
this truncated GHR plays a role in signal transduction.
Both JAK2 and a multitude of other, mostly high molecular weight, proteins are
activated and interact with both wtGHR and GHR 1-369 after GH induction in acid-
wash treated cells. Co-immunoprecipitation of GH-GHR-JAK2 complexes, after
uptake by the cells, shows that JAK2 is not only bound to the GHR at the cell-sur-
face but also intracellularly, suggesting that the receptor and some of its signal
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transducing molecules might still be active in endosomes. A smear of phosphory-
lated proteins attached to the GH-GHR complex inside the cells confirmed the
receptor's capacity of signaling. Intracellularly, the pattern of phosphorylated pro-
teins in wtGHR and GHR 1-369 is similar, providing both receptors comparable
signaling capabilities.
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Abstract 
The ubiquitin-proteasome system is required in growth hormone receptor endocy-
tosis. For cytokine receptors, which lack intrinsic tyrosine kinase activity, signal
transduction is initiated by the activation of a member of the JAK family.
Previously, we have shown that GHR and JAK2 tyrosine (de)phosphorylation are
regulated via the ubiquitin system. In this study, we examined the role of JAK2-
mediated signal transduction in GHR internalization and downregulation. Mutation
of the attachment site for JAK2, box-1, in the GHR cytoplasmic tail resulted in the
complete absence of GHR and JAK2 phosphorylation. This modification did not
alter the rate and extent of receptor-bound GH internalization as compared to a
functional GHR, nor did it change its turnover and transport to the plasma mem-
brane. In addition, the receptor was still normally ubiquitinated and remained
dependent on both an intact ubiquitin system and on proteasomal action for its inter-
nalization. Thus, GHR ubiquitination, endocytosis and degradation occur inde-
pendently of GHR signal transduction via JAK2. We conclude that, while endocy-
tosis and degradation require the ubiquitin system, they are independent of GHR
signal transduction.
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Introduction
GH regulates important physiological processes such as growth, metabolism and
cellular differentiation. The actions of GH are mediated through activation of the
GHR, a member of the cytokine/hematopoietin receptor superfamily with homolo-
gies defined in the extracellular domain and that lacks intrinsic tyrosine kinase
activity in its intracellular domain (1-3). Upon GH binding, the dimerized complex
associates with the tyrosine kinase JAK2, a member of the Janus family of cytoso-
lic kinases (3-5). GH-dependent tyrosine phosphorylation of JAK2 itself, GHR, and
of other cellular proteins depends on the receptor's ability to activate JAK2 (3-9).
Biochemical evidence has shown that JAK2 activation by the GHR is essential for
activating the STAT proteins, several proteins involved in the Ras/MAP kinase
pathway, as well as the insulin receptor substrate proteins IRS-1 and IRS-2, which
initiate the PI-3 kinase pathway (4, 9, 10, 11). So far, only the GH-dependent effect
on calcium entry appears to involve mechanisms independent of JAK2 activation
(12). Since a C-terminally truncated receptor, able to interact with and to activate
JAK2, was unable to activate specific signaling molecules, like STAT5 (13), acti-
vation of JAK2 alone is insufficient to elicit all of the responses to GH, suggesting
that such proteins are unlikely to be direct JAK2 substrates.
A proline-rich motif termed box-1, between amino-acids 297-311, is conserved
within members of the cytokine family and is required for the association of JAK2
with GHR as well as GH-dependent activation of JAK2 (1, 4, 14). Studies using
mutated box-1 regions of the GHR have shown that this region is intermediate in
GH-dependent association and activation of JAK2 (4, 7). Although box-1 is suffi-
cient to bind and activate JAK2, a maximal JAK2 activation requires downstream
residues in the half-proximal part of the GHR cytoplasmic domain. This more dis-
tal region appears to stabilize the interaction between the receptor and JAK2.
Within box-1, no specific residue seems, in itself, crucial for the association.
Mutation of each individual proline residue nor simultaneous mutation of the first
two prolines in box-1 did impair JAK2 association to the receptor. On the other
hand, simultaneous mutation of the 4 prolines abolished the capacity of the recep-
tor to interact and to activate JAK2, as well as other signaling proteins (4, 15, 16).
Thus, the proline-rich region is critical for GH signal transduction. 
After binding to its receptor, GH internalizes via clathrin-coated pits and is degra-
ded in lysosomes (17,18). This process is regulated by both the ubiquitin system and
the proteasome (19-22). For other signaling receptors containing tyrosine kinase
activity, like the epidermal growth factor (EGF) (23) and G protein-coupled recep-
tors (24, 25), it was shown that kinase activity is necessary for their maximal inter-
nalization rate. In the EGF receptor, mutation of its intrinsic tyrosine kinase activi-
ty abolished both signaling transduction and ligand-induced downregulation/endo-
cytosis (26, 27), while other receptors (e.g. transferrin) were internalized through
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coated pits without any known kinase requirement (23). 
Until now a role for JAK2 kinase activity of the GHR in endocytosis has not been
described. The role of box-1 in endocytosis is unclear and mutations in box-1 may
lead to a block of GHR endocytosis (15). Recently, we observed that signalling of
GHR/JAK2 is also regulated by the proteasome, as proteasomal inhibitor MG132
prolongs the GH-induced activity of both GHR and JAK2, presumably through sta-
bilization of GHR and JAK2 tyrosine phosphorylation. If proteasomal inhibitor was
combined with ligand in an endocytosis-deficient GHR mutant, the same pheno-
mena occurred indicating that proteasomal action on tyrosine dephosphorylation is
independent of endocytosis (28). To determine the role of JAK2-mediated signal
transduction in GHR internalization and downregulation, we replaced the four pro-
line residues in box-1 with alanines (GHR4P-A). Modification of the box-1 resulted
in the complete absence of GHR and JAK2 phosphorylation. We demonstrate that
the GHR4P-A mutant behaves in a similar manner as the wtGHR. GHR4P-A presents
presents the same internalization kinetics as wtGHR, it is ubiquitinated normally,
and depends on an intact ubiquitin system as well as on the proteasome for its inter-
nalization. 
Experimental Procedures
Cells and Materials
Chinese hamster ts20 cells were stably transfected with the full-length rabbit GHR
cDNA sequence as described previously (19), as well as a cDNA encoding for a
GHR mutation on box-1 (see mutagenesis and transfection). Due to a thermolabile
ubiquitin-activating enzyme (E1), the ubiquitin conjugating system is inactive in
these cells at the non-permissive temperature of 420C. Stable geneticin-resistant
transfectants were grown in Eagle's minimal essential medium (MEMα) supple-
mented with 10% fetal bovine serum, penicillin and streptomycin, 3.5 g/liter glu-
cose and 0.45 mg/ml geneticin. For experiments, cells were grown in the absence
of geneticin to approximately 80% confluence. Anti-GHR antiserum was raised
against amino acids 271-381 (anti-GHR(T)) of the cytoplasmic tail as previously
described (19). Antibody recognizing the lumenal part of the GHR (Mab5) was
from AGEN Inc., Parsippany, NJ. Antiserum against JAK2 was raised in rabbits as
described in (29). Polyclonal antibody against JAK2 and phosphotyrosine (4G10,
anti-PY) were obtained from Upstate Bio-technologies Inc. (Lake Placid, NY). GH
antiserum was from DAKOPATTS and antiserum specific for protein-ubiquitin con-
jugates was a generous gift from Dr. A. Ciechanover (Technion-Israel Institute of
Technology, Haifa, Israel). hGH was a gift of Lilly Research Labs, Indianapolis, IN.
Culture medium, fetal calf serum (FCS) and geneticin were purchased from Gibco.
MG132 was purchased from CalBiochem.
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Mutagenesis and transfection
The signaling-deficient mutant GHR4P-A was constructed by QuickChange mutage-
nesis (Stratagene), using a 5' oligonucleotide and a 3' oligonucleotide containing the
unique restriction site KpnI. This GHR cDNA was cloned into pcDNA3 vector
(Invitrogen), sequenced and transfected into ts20 cells at 30% confluence using the
calcium phosphate transfection method. After transfection, individual clones were
selected in geneticin based on the amount of GH binding and by immunoblotting
cell extracts with an antibody to the N-terminus of the GHR.
GH binding and internalization
125I-labeled hGH (125I-GH) was prepared by using chloramine T (19). Cells were
grown in 35-mm dishes, washed and incubated with MEMα supplemented with 20
mM Hepes (MEMα/Hepes) and 0.1% bovine serum albumin (BSA) for 1 hour at
300C, and further incubated for 1 hour on ice with 8 nM 125I-GH in MEMα/Hepes,
in the absence or presence of excess unlabeled GH. The cells were washed free of
unbound GH and incubated from 0 to 1 hours at 300C. The cells were washed with
ice-cold PBS, membrane-associated GH was removed by acid wash (0.15 M NaCl,
0.05 M glycine, pH 2.5), and internalized GH was determined by measuring the
radioactivity after solubilization of the acid-treated cells by 1 M NaOH. The cell
extracts were counted in a LKB gamma counter.
Microscopy
Cy3-GH was prepared using a FluoroLink Cy3 label kit according to the supplier's
instructions (Amersham Pharmacia Biotech.). Transfected ts20 cells, grown on cov-
erslips, were incubated for 1 hour in MEMα/Hepes at either 300C or at the non-per-
missive temperature of 420C, and then incubated for 30 min in the presence of Cy3-
GH (1 µg/ml). If necessary, MG132 (20 µM) dissolved in ethanol, was added 1 hour
before the start of the experiment. Cells were washed with PBS to remove unbound
label and fixed for 2 hours in 3% paraformaldehyde in PBS. After fixation, the cells
were embedded in Mowiol, and confocal laser scanning microscopy was performed
using a Leica TSC 4D system.
Cell lysis, immunoprecipitation and western blotting
Cells, grown in dishes, were lysed on ice in lysis buffer containing 1% Triton X-
100, 1 mM EDTA, 1 mM Na3VO4, 50 mM NaF, 10 µg/ml aprotinin, 10 µg/ml leu-
peptin, and 1 mM phenylmethylsulfonyl fluoride in PBS. The lysates were cleared
by centrifugation. In ubiquitin blotting experiments, the cells were lysed in boiling
lysis buffer containing 1% SDS in PBS in order to minimize isopeptidase activity.
The lysate was heated at 1000C for 5 min, sheared to break all DNA, and cen-
trifuged for 5 min at 10,000 x g. Immunoprecipitations were carried out in 1%
Triton X-100, 0.5% SDS, 0.25% sodium deoxycholate, 0.5% bovine serum albumin
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(BSA), 1 mM EDTA, 1 mM Na3VO4, 50 mM NaF, 10 µg/ml aprotinin, 10 µg/ml
leupeptin, and 1 mM phenylmethylsulfonyl fluoride in PBS. Reactions were incu-
bated with GHR(T) or JAK2 antiserum for 2 hours at 00C. Protein A-agarose beads
(Repligen Co., Cambridge, MA) were used to isolate the immuno-complexes. The
immunoprecipitates were washed twice with the same buffer and twice with 10-fold
diluted PBS. For co-immunoprecipitations, cells were lysed in 0.1% Triton X-100,
0.5% BSA, 1 mM EDTA, 1 mM Na3VO4, 50 mM NaF, 10 µg/ml aprotinin, 10
µg/ml leupeptin and 1 mM phenylmethylsulfonyl fluoride in PBS. The lysates were
further incubated with GH antibody for 2 hours and the immuno-complexes were
isolated through protein A-agarose beads. All immuno-complexes were analyzed
through 7.5% polyacrylamide gel electrophoresis in the presence of SDS (SDS-
PAGE) together with total cellular lysate and transferred to polyvinylidene difluo-
ride paper. The blots were immunostained with either Mab 4G10 (anti-PY), anti-
ubiquitin, anti-GHR, or commercial JAK2 antibody. After incubating the blots with
rabbit anti-mouse IgG (RAMPO) or protein A conjugated to HRP, antigens were
visualized through the ECL system (Boehringer Mannheim).
Metabolic labeling
For metabolic labeling, the cells were incubated in methionine-free MEM for 30
min and then [35S]methionine (3.7 MBq/ml TRAN-35S labelTM, 40 TBq/mmol,
ICN, Costa Mesa, CA) was added and labeled for 10 min at 300C in a CO2-incuba-
tor. The radioactivity was chased for different times with or without 8 nM GH in the
presence of MEMα containing 0.1 mM unlabeled methionine and 0.1% BSA. The
radioactivity was determined using a StormTM imaging system (Molecular
Dynamics, Sunnyvale, CA) and quantified with Molecular Dynamics Image
QuaNT software version 4.2a.
Results
JAK2 binding and activation is absent in a box-1 mutated GHR
To determine whether activation of the GHR and downstream signaling compo-
nents are involved in GH-dependent endocytosis, the 4 proline residues between
amino-acids 280-287 in box-1 of the cytosolic tail of the GHR were mutated to ala-
nines (GHR4P-A). An intact box-1 is required for the association of JAK2 with GHR
and GH-dependent activation of JAK2 (4, 7). A ts20 cell line stably expressing
GHR4P-A with approximately the same number of GH binding sites at the cell-sur-
face as the wild-type GHR ts20 cell line was used in this experiment. Immunoblot
analysis of cellular extracts from both cell lines demonstrated that the mutant recep-
tor expressed a GHR protein of the expected molecular size and that the level of
total cell expression was comparable (Fig. 1A). To ascertain that the GHR4P-A
mutant was unable to respond to GH, the tyrosine phosphorylation of the GHR was 
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assayed. As shown in Fig. 1A, no PY signal was detectable on the 130 kDa GHR4P-
A mutant upon GH stimulation, in contrast to wtGHR expressing cells. As a nega-
tive control, untransfected ts20 cell lines were used. Similarly, JAK2 did not
become tyrosine phosphorylated upon GH in cells expressing the GHRP-A (Fig. 1B). 
Box-1 is, therefore, essential for activation of both JAK2 and GHR, confirming pre-
viously published results (4, 7). To test the capacity of the GHR4P-A to activate sig-
naling molecules other than JAK2, a co-immunoprecipitation of GH-GHR com-
plexes was performed and blotted for phosphotyrosine proteins (Fig. 2). As expec-
ted, the inactive GHR4P-A did not display the same phosphorylated bands as seen for
the wtGHR, indicating that, indeed, the mutant receptor lacked signaling activity.
GH (min): 0 15 60 0 15 60 0 15 60
GH (min): 0 15 60 0 15 60 0 15 60
ts20
ts20
IP: anti-GHR (T)
anti-GHR
(Mab5)
wtGHR GHR4P-A
wtGHR GHR4P-A
anti-PY mGHR
mGHR
PGHR
GH (min): 0 15 0 15 0 15
GH (min): 0 15 0 15 0 15
anti-PY
anti-JAK2
IP: anti-JAK2
JAK2
JAK2
A
B
Fig. 1. Box-1 is required for jAK2 binding and
activation
Untransfected ts20, ts20 cells expressing the
wtGHR and GHR4P-A cell lines were stimulated
with 8 nM hGH at 30°C for the time periods indi-
cated. Cell lysates were prepared and subjected to
immunoprecipitation (IP) of the GHR by using
anti-GHR(T) (A) or of JAK2 by using anti-JAK2
serum (B) and then subjected to immunoblot
analysis with an antibody against phosphotyrosine
residues (anti-PY). The PY blots were reblotted
with anti-GHR(Mab5) or anti-JAK2, respectively.
Arrows indicate mature (mGHR) and precursor
(pGHR) forms of the GHR. 
ts20
GH (min): 0 15 60 0 15 60 0 15 60
GH (min): 0 15 60 0 15 60 015 60
anti-PY
anti-GHR
(Mab5)
IP: anti-GH
wtGHR GHR4P-A
mGHR
mGHR
pGHR
Fig. 2. Tyrosine phosphorylation capac-
ity of GHR4P-A cells. 
Ts20 cells and cells expressing wtGHR
and GHR4P-A were incubated at 30°C with
or without 8 nM hGH for the time periods
indicated. Cells were lysed and GH-GHR
complexes were co-immunoprecipitated
with an antibody against GH (anti-GH),
blotted with anti-PY (upper panel) and
reblotted with anti-GHR (Mab5) (lower
panel). Arrows indicate mature (mGHR)
and precursor (pGHR) forms of the GHR.
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JAK2 tyrosine kinase activity is not required for GH-dependent internaliza-
tion of GHR.
To determine whether JAK2 tyrosine kinase activity is required for ligand-induced
internalization, the uptake of 125I-GH was performed in cell lines expressing either
wtGHR or the GHR4P-A mutant. As seen in Fig. 3, the percentage of internalization
reached 50% after 30 min of GH induction for the wtGHR. In two independent cell
lines, the rate of GH internalization for the box-1-mutated GHR was similar or
higher than that of wild-type receptors. In order to exclude a possible contribution
of receptor recycling, GH internalization was measured during the first 10 min of
GH uptake and gave similar results for both types of receptors (not shown). In addi-
tion, the extent and rate of GH degradation were unaltered, indicating that JAK2
activation and GHR phosphorylation play no role in the transport of the ligand to
the lysosomes. GHR4P-A internalization bound GH as efficiently as wtGHR, indi-
cating that tyrosine phosphorylation of the GHR is not required for GH-dependent
GHR internalization.
To approach the same question in a different way, a fibroblastoma cell line deficient
in JAK2 (γ2A) and its parental cell line containing JAK2 (2C4) transiently trans-
fected with wtGHR were also tested for GH-uptake. Both cell lines showed the
same endocytosis rates of 125I-GH as observed for the GHR4P-A mutant (not shown).
Box-1 is not involved in GHR turnover
Next, we assessed the life-cycle of both the wtGHR and the GHR4P-A mutant at 300C
through pulse-chase labeling with [35S]methionine (Fig. 4). The wtGHR is synthe-
sized as an 110 kDa glycoprotein precursor and thereafter converted to an 130 kDa
mature species. For both the wtGHR and the GHR4P-A, the mature form was
detectable at 20 min of chase and is maximal at 60 min, whereafter rapid degrada-
tion occurred (Fig. 4 A and B). These results demonstrate that both receptors have 
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Fig. 3. Internalization kinetics of wtGHR and GHR4P-A. 
GH internalization was quantitated by [125I]GH uptake. WtGHR cells (closed symbols) and GHR4P-A
(open symbols) were incubated with 8 nM [125I]GH in the absence or presence of excess unlabeled
GH for the indicated periods of time at 300C. Specific internalized [125I] GH was expressed as the per-
centage of total radioactivity. TCA-soluble radioactivity in the incubation medium was determined and
expressed as the percentage of total cell-associated and TCA-soluble label at 60 min.
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a fast turnover with a half-life of 45-60 min and that maturation and transport to the
plasma membrane were not affected by a mutated box-1 in the GHR. To determine
whether GH affects receptor turnover, the same experiment was performed in the
presence of GH (Fig. 4, C and D). GH slightly accelerated degradation of the
wtGHR mature form (Fig. 4C), as compared to GHR4P-A (Fig. 4D). 
Box-1 and ubiquitin/proteasome system-dependent internalization 
Using ts20 cell lines, we showed previously that an active ubiquitin/proteasome
system is essential for wtGHR internalization (19, 22). To elucidate this further,
immunofluorescence studies were performed following the uptake of cy3-labeled
GH for 30 min (Fig. 5). As a control, wtGHR cells were used (Fig. 5, A, B, C),
clearly demonstrating an inhibition of internalization upon MG132 or 420C pre-
incubation, similar to previous results (19, 22). For the GHR4P-A mutant cells (Fig.
5, D, E, F), both treatments induced similar inhibitory effects as for the wtGHR.
Fig. 5D confirms the results presented in Fig.3, clearly showing a normal ligand
internalization staining pattern. Under conditions where either the proteasomes
were inhibited (MG132) or the ubiquitin system was blocked (420C), cy3-GH-
dependent GHR4P-A mutant internalization was inhibited. To test whether kinase
activity plays a role in GHR internalization, both cy3-GH and Texas Red-labeling
Fig. 4. Pulse-chase labeling with [35S]methionine
of both wtGHR and GHR4P-A.
WtGHR and GHR4P-A-expressing cells were pre-
incubated with methionine-free MEMα for 30 min,
labeled with [35S]methionine for 10 min at 300C and
chased in the absence of radioactivity in MEMα
supplemented with 0.1% BSA, 100 µM methionine
with or without 8 nM GH for the indicated times.
Cell lysates were immunoprecipitated with anti-
GHR antibody (anti-GHR(T)). (A), wtGHR and (C),
GHR4P-A; P, precursor GHR (110 kDa); m, mature
GHR (130 kDa). Radioactivity was quantified by
using ImageQuant (Molecular Dynamics) and
expressed as a percentage of the radioactivity incor-
porated in the precursor GHR after the pulse label-
ing during time. B, precursor wtGHR is represented
in absence of GH by closed circles and in presence
of GH by open circles. Mature wtGHR is represen-
ted in absence of GH by closed squares and in pre-
sence of GH by open squares. D, precursor GHR4P-
A is represented in absence of GH by closed circles
and in presence of GH by open circles. Mature
GHR4P-A is represented in absence of GH by closed
squares and in presence of GH by open squares.
wtGHR
GHR4P-A
IP: anti-GHR(T)
IP: anti-GHR(T)
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transferrin, used to control cellular transport, were measured in wtGHR cells trea-
ted in absence or presence of the kinase inhibitor staurosporine (not shown). Indeed,
staurosporine had no effect on the internalization of either ligand, suggesting that
tyrosine kinase activity is not essential for GHR endocytosis.
Ubiquitination of the GHR is independent of its phosphorylation and signal
transduction
To determine whether GHR signaling is involved in receptor ubiquitination, we
tested whether the GHR4P-A mutant was ubiquitinated upon GH stimulation. As
shown in Fig.6, in the presence of GH, wtGHR was ubiquitinated at the permissive
temperature but not ubiquitinated at the non-permissive temperature of 420C.
Similar results were obtained for the GHR4P-A. Thus, the ubiquitin-proteasome sys-
tem does not require JAK2 action nor its presence on the dimerized GHR for its
action to stimulate receptor endocytosis. In conclusion, GHR signal transduction
via JAK2 is independent of ubiquitination, endocytosis and degradation.
Discussion
The GHR is a member of the cytokine/hematopoietin receptor superfamily, defined
on the basis of a limited amino acid homology. In the intracellular domain of se-
veral members of this superfamily situated close to the plasma membrane, a pro-
line-rich motif eight amino acids residues long, referred to as box-1, has been re-
cognized as being involved in signal transduction (4, 7). The association of JAK2
to box-1 of the GHR, activation of the dimerized JAK2 kinase, and JAK2 autophos-
phorylation are all early steps in the signaling pathway (6). The central role of JAK2
in GH signaling is evident from studies using mutated GHRs which failed to bind
or activate JAK2 and downstream effectors like SHC (Src homology (SH)-2 con-
Fig. 5. Visualization of
Cy3-GH uptake by confo-
cal microscopy 
Ts20 cells, expressing
WtGHR (A-C) or GHR4P-A
(D-F) were incubated for 1
hour at 30 (A and D) or 420C
(C and F) or incubated with
20 µM MG132 at 300C (B
and E). Cy3-GH was then
added for 30 min, the cells
were washed, fixed, and the
fluorescence was visualized
by confocal microscopy.
A
wtGHR
B
wtGHR
C
wtGHR
D
GHR
4P-A
E
GHR
4P-A
F
GHR
4P-A
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taining protein), MAP, STAT, and IRS (4, 9, 10, 11, 30). 
The results of our experiments shown in Fig. 1, confirm that JAK2 can be specifi-
cally tyrosine phosphorylated in response to GH. Mutation of the four prolines of
box-1 region at the membrane proximal domain of the cytoplasmic tail of the GHR
abrogated JAK2 association with the GHR cytoplasmic domain as previously
demonstrated (4). Although mutation of the box-1 region in the GHR did not affect
the ability of the altered receptor to bind GH at the cell-surface, it dramatically
affected the receptor's capacity to couple GH binding to JAK2 activation and con-
sequently of other possible signaling molecules (Fig. 2). Interestingly, the biologi-
cal responses of the GHR expressed in a variety of cell types (i.e. activation of MAP
kinase, activation of c-fos gene expression, increased protein synthesis, lipid syn-
thesis, and cellular proliferation), have not been observed for the GHR mutant of
the box-1 region (30, 31, 32). 
In contrast to what has been found with other families of signal-transducing growth
factor receptors (e.g., EGF receptor), GH-stimulated JAK2 kinase activity and tyro-
sine phosphorylation of the GHR itself were not required for efficient GH-depen-
dent internalization of the GHR (Fig. 3). A previous report suggested that mutations
in box-1 may lead to a block of GHR endocytosis (15). In this study, the specific
initial rate of internalization of the GHR4P-A appears to be nearly the same as for
normal receptor. Furthermore, as observed in Fig. 3, GH is still normally targeted
for degradation in GHR4P-A, indicating that transport to the lysosome is not affec-
ted in box-1-defective receptors. The GHR4P-A turnover also does not differ from the
wtGHR, suggesting that, once-internalized, intracellular sorting destinations of
inactive receptor isoforms do not differ from those of functional receptor isoforms.
However, upon GH stimulation, wtGHR mature form showed relatively faster
degradation, while addition of GH had no such clear effect on the turnover of the
GH: + + - + - + - + - +
GH: + + - + - + - + - +
ts20
anti-Ubi
IP: anti-GHR(T)
anti-GHR
(Mab5)
wtGHR GHR4P-A
30 42 30 42 30 42 ( C)0
mGHR
mGHR
PGHR
Fig. 6. Effect of box-1 mutation
in the GHR on ubiquitination.
Cells expressing wtGHR and
GHR4P-A were incubated for 1
hour at 30 of 420C and treated
with 8 nM GH for 30 min. After
lysis, GHR was immunoprecipi-
tated with anti-GHR (T) and ana-
lyzed by Western blotting using
an anti-ubiquitin conjugate
serum (anti-Ubi). As a control,
untransfected cells (ts20) were
subjected to the same procedure.
A reblot with anti-GHR (Mab5)
is shown on the lower panel.
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GHR4P-A (Fig. 4). This result suggests that GH-dependent wtGHR accelerated
degradation is mediated through a JAK2-dependent process that is absent in GHR4P-
A, indicating that signal transduction is contributing to a faster endocytosis/degra-
dation of the GHR. This might be due to the fact that the signal transduction path-
way via STAT or MAP kinase stimulates the clathrin-mediated endocytosis, a phe-
nomenon known from the EGF receptor studies (33).
Previously, we showed that the ubiquitin system is required for ligand-induced
GHR internalization (19). In particular, a specific 10 amino-acid sequence between
amino acid 323 and 332 termed the UbE motif within the GHR cytosolic tail is
involved in both GHR ubiquitination and ligand-induced endocytosis (21). GHR
internalization requires the recruitment of the ubiquitin conjugation system to the
UbE motif. Recently, we showed that the proteasome is also involved in GHR
downregulation (22). Specific proteasomal inhibitors block GH uptake of the full-
length GHR, while a truncated receptor can endocytose undisturbed. Using ts20
cells, we determined whether the endocytosis of an inactive GHR is still inhibited
upon inactivation of the ubiquitin system or upon inhibition of the proteasome with
MG132. Our results show that at the non-permissive temperature, with an impaired
ubiquitin system, GHR4P-A internalization was still inhibited as previously observed
for the wtGHR (Fig. 5) (19). Thus, GHR/JAK2 signal transduction plays no role in
the binding of the E2/E3 enzymes, members of the ubiquitin conjugation system, to
the receptor (Fig. 3). Similarly, the proteasomal inhibitor MG132 prevented GHR4P-
A endocytosis as previously determined for the wtGHR (Fig. 5) (22). This suggests
that the motif at the GHR tail responsible for the proteasome action (amino acids
369-399) (22) does not interact with signaling proteins nor is such an interaction or
phosphorylation itself important for the proteasome action. Furthermore, both
wtGHR and mutated receptor are ubiquitinated upon GH binding (Fig. 6). Together,
these results demonstrate that the molecular mechanism which underlies the ubi-
quitin-proteasome system-dependent endocytosis of the GHR does not require the
presence nor the activity of JAK2 and its signalling molecules.
In a recently published work, we showed that proteasomes are involved in the
downregulation of the GHR activation signals (28). The endocytosis-deficient
receptor GHR F327A, was still able to become phosphorylated and to induce sig-
nal transduction. Surprisingly, its signal transduction was still downregulated at the
cell-surface, indicating that it occurs independent of endocytosis. However, protea-
somal inhibitors prevented GHR and JAK2 dephosphorylation at the cell-surface.
We concluded that the ubiquitin-proteasome system is a regulator of JAK2 signal
transduction, probably via suppressors of cytokine signalling (SOCS). Thus, the
ubiquitin-proteasome system independently regulates the signal transduction capa-
city of the GHR in two ways: first, it determines the rate of endocytosis via the
UbE-motif in the GHR tail, and second, it determines the signaling time via JAK2
and SOCS. Both mechanisms appear to be independently regulated by the same sys-
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tem, probably via completely different E2/E3 enzyme systems. 
In other systems, e.g. the EGF receptor, association of the adapter protein Grb2 is
required for receptor endocytosis. Grb2 associates with the cytoplasmic tail of the
EGF receptor after stimulation by EGF, leading to activation of the Ras/MAPK sig-
nalling pathway. Grb2 also indirectly associates with the GHR via SHC in the
region that maps to the distal cytoplasmic tail (amino acids 454-620) (35). Cells
expressing truncated receptors that lack this domain and therefore unable to associ-
ate with Grb2, can internalize the truncated receptor as efficiently as cells contain-
ing wtGHR. Thus, in addition to the dispensability of JAK2 activity and receptor
tyrosine phosphorylation, recruitment of Grb2 to the receptor and activation of the
MAPK pathway is also not required for GHR downregulation. Similarly, EGF-sti-
mulated activation of Src kinase leads to tyrosine phosphorylation of clathrin, and
as phosphorylation is required to recruit clathrin to the membrane, this observation
strongly suggests a role for c-Src in EGF receptor endocytosis (34). This is not the
case for the GHR4P-A, since inhibition of JAK2 and consequently of Src does not
affect GHR clathrin-dependent endocytosis. Furthermore, it has recently been pu-
blished that neither activation of the erythropoietin receptor, another member of the
cytokine family, nor JAK2 tyrosine kinase activity are required for internalization
of bound erythropoietin (36). Taken together, these results suggest that, for signal-
ing receptors of the cytokine receptor superfamily, endocytosis follows a pathway
distinct from signaling receptors of the RTK family.
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Abstract
Oxidative stress activates the ubiquitin-proteasome system, and increases the cellu-
lar levels of ubiquitin-protein conjugates at the expense of free ubiquitin. In this
report we demonstrate that growth hormone receptor (GHR) levels are reduced in
cells subjected to oxidative stress. H2O2 treatment induced a decrease in the num-
ber of GHRs at the cell-surface, by both delaying its transport to the plasma mem-
brane, and enhancing shedding activity. Both effects are independent of the UbE
motif of the GHR as, upon stress, the endocytosis-deficient GHR-F327A behaves in
a similar manner. These findings indicate that cells contain stress-induced mecha-
nisms that regulate GHR availability at the cell-surface and diminish its biological
activity, like protein synthesis and cellular growth, in order to enable the cell to
recover from oxidative stress.
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Introduction
The response of a cell to its external environment requires rapid and significant
alteration of protein amount, localization and/or function. Several tightly regulated
processes control synthesis, localization and degradation of such proteins. The
ubiquitin-proteasome system is involved in intracellular proteolysis, cell cycle re-
gulation, cellular growth and differentiation, receptor function, development and
the stress response. Substrates regulated by this system include several cyclins,
tumor suppressors, transcription factors, and cell-surface receptors. The target pro-
teins are first tagged with ubiquitin molecules to form a polyubiquitin chain, which
is specifically recognized by the multi-subunit proteasome complex, leading to their
degradation. Attachment of ubiquitin was found to be important in defending
against cellular damage caused by external influences including environmental
insults, elevated temperatures, heavy metals, amino acid analogs, viral infection,
oxidative and chemical damage, infections and mutations (1-4). In general, tran-
scriptional induction of a set of genes whose products, known as stress proteins,
enhances survival under stress conditions (for review: 5). Certain components of the
ubiquitin pathway were found to be stress proteins, including ubiquitin itself and
specific E2 enzymes, which expression is up-regulated in stressed cells (6).
Imposition of stress is usually accompanied by a dramatic redistribution of ubiqui-
tin, such that most of the ubiquitin in the cell becomes conjugated to substrate pro-
teins (1, 7, 8). In yeast, the E2's UBC5 and UBC5 genes are important for the ubi-
quitination and turnover of normal short-lived proteins (6), but they are also
involved in heat-shock and cadmium induced stress (2, 6). No E3 enzymes have yet
been identified as stress proteins, nor has any E3 been shown to play an important
role in the stress response. Protein synthesis inhibitors like cycloheximide, do not
prevent stress-induced ubiquitin redistribution, suggesting that this event is mainly
due to increased susceptibility of proteins to ubiquitination. However, up-regulation
of ubiquitin and E2s might also contribute to increased conjugate levels (8). 
Particularly, upon oxidative stress, both protein ubiquitination and proteasomal
degradation have been demonstrated (8, 9). Oxidative stress damages cells, and has
been implicated in several processes, including degenerative diseases of aging,
Alzheimer's and Parkinson's disease, arthritis, atherosclerosis, and cancer (10-15).
The exposure of cells to high levels of oxygen free radicals results in damage of
proteins, lipids, DNA, and enzyme activity, affecting both cell proliferation and dif-
ferentiation. Proteins containing free cysteine residues are targets for oxidants,
where, for instance, phosphorylation/dephosphorylation activities are affected.
Several proteins involved in signal transduction, including MAPKs, Raf-1, Ras, and
growth factor receptors, such as the epidermal growth factor receptor (EGFR) and
platelet-derived growth factor receptor (PDGFR), are phosphorylated and activated
upon oxidative stress (16-20). For both the EGFR (21) and the chicken hepatic
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lectin (CHL) receptor, that mediates endocytosis of glycoproteins terminating with
N-acetlyglucosamine, ligand-dependent internalization was shown to become
inhibited upon hydrogen peroxide (H2O2) stress (22). Possibly, H2O2 inhibits EGFR
internalization by inhibition of Eps15 ubiquitination, known to be involved in the
internalization process (21). It is thought that the increased EGFR phosphorylation
upon H2O2 exposure, is a result of tyrosine phosphatase inactivation (19, 23).
Following cellular exposure to oxidants, the levels of the cellular sulfhydryl reduc-
tant glutathione (GSH) decrease, while the levels of its oxidized form (GSSG)
increase. Upon severe oxidative stress, ubiquitination of proteins is also decreased,
suggesting that oxidative stress interferes with E1/E2 activities (24, 25). These
enzymes contain active site sulfhydryls that might be covalently modified (thiolat-
ed) upon enhancement of GSSG levels (glutathiolation). Glutathiolation might reg-
ulate the levels of ubiquitinated proteins in response to oxidative stress (25).
Previously, we have shown that the ubiquitin system is required for ligand-induced
growth hormone receptor (GHR) internalization (26). In the presence of ligand,
GHR endocytoses rapidly via clathrin-coated pits (27), and its degradation occurs
at least partially within the lysosome (28). In a chinese hamster cell line carrying a
temperature-sensitive E1 enzyme (ts20 cells), inactivation of E1 results in accumu-
lation of non-ubiquitinated GHRs at the plasma membrane, while internalization of
the transferrin receptor is unaffected (26). Therefore, binding of GH induces ubi-
quitination, internalization and degradation of the GHR. A 10 amino acid motif,
including Phe-327 within the GHR cytosolic tail (UbE motif), was found to be
involved in both receptor ubiquitination and GH-induced receptor endocytosis (29).
Mutation of Phe-327 leads to an inhibition of receptor ubiquitination and endocy-
tosis. In addition to an active ubiquitin conjugation system, GHR internalization
requires proteasomal action (30). Specific proteasomal inhibitors block GH uptake
of the full-length GHR, while a truncated receptor can endocytose undisturbed. In
addition, ubiquitination of the GHR itself does not seem to be important for inter-
nalization, as a truncated GHR with all its lysines mutated to alanines, was still able
to internalize GH (31).
In this report, we addressed the role of oxidative stress on the turnover of the GHR.
We show that upon H2O2 treatment, levels of ubiquitin-protein conjugates
increased, while free ubiquitin decreased. As a consequence, GHR levels at the cell-
surface decreased while GHR precursor forms in the cell remained unaffected, both
by delaying its transport to the plasma membrane and inhibiting its downregulation
from the cell-surface; in addition, the amount of growth hormone binding protein
(GHBP) was increased. Furthermore, we observed that this effect was independent
of the UbE motif of the GHR as, upon stress, the GHR-F327A behaviour is similar
to the wtGHR. In absence of ligand, a small percentage of the GHRs at the cell-sur-
face was ubiquitinated (29). However, stress and the consequent activation of the
ubiquitin system did not increase the receptor's downregulation by triggering endo-
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cytosis, but instead, influence the turnover of the receptor in the cell. 
Experimental Procedures
Cells and Materials
Chinese hamster ts20 cells, containing a thermolabile ubiquitin-activating enzyme
E1, were stably transfected as described previously (26). The internalization-defi-
cient mutant GHR-F327A was constructed by site-directed mutagenesis, cloned and
transfected into ts20 cells as described before (29). Stable, geneticin-resistant trans-
fectants were grown in Eagle's minimal essential medium (MEM-α) supplemented
with 10% fetal bovine serum (FCS), penicillin and streptomycin, 4.5 g/liter glucose,
and 0.45 mg/ml geneticin. For experiments, cells were grown in the absence of
geneticin at approximately 70% confluence.
Antibody to GHR was raised against amino acids 271-381 of the cytoplasmic tail
(anti-GHR(T)) as previously described (26). Antibody (Mab5) recognizing the
lumenal part of the GHR was from AGEN Inc., Parsippany, NJ. Antiserum against
human GH was raised in rabbits. Antiserum specific for protein-ubiquitin conju-
gates was a generous gift from Dr. A. Ciechanover (Technion-Israel Institute of
Technology, Haifa, Israel). The GH antagonist, B2036, was kindly supplied by
Willem F. Bennett of Sensus Drug Development Corporation (Austin, TX). Culture
medium, fetal calf serum (FCS), geneticin and hydrogen peroxide (H2O2) were pur-
chased from Gibco. LipofectAMINE was from Life Technologies, Inc. Transferrin
(Tf) was purshased from Sigma (St. Louis, MO).
Plasmids and transfection
Wild-type human GH cDNA was cloned into pcDNA3.1 vector (Invitrogen
BV/Novex), and used for transiently transfections. Subconfluent cultures of ts20
cells were 30% confluent when transfected with 1 µg cDNA per dish, using
LipofectAMINE according to the protocol. Cells were used for experiments 48
hours after transfection.
B2036 binding and internalization
125I-labeled GH antagonist (125I-B2036) was prepared by using chloramine T (19).
Ts20 cells stably transfected with wtGHR, were grown in 12 well-plates, washed
and incubated with MEMα supplemented with 20 mM Hepes (MEMα/Hepes), 10%
FCS, and 4.5 g/liter glucose with or without 10 mM H2O2 for 30 min at 300C. A
short incubation of 6 min with 8 nM 125I-B2036 in MEMα/Hepes in the absence or
presence of excess unlabeled GH, was followed by different periods of chase from
0 to 1 hour at 300C. At the indicated times, the medium was collected and precipi-
tated with one volume of ice-cold 20% trichloroacetic acid (TCA) for 30 min on ice.
Acid soluble and insoluble radioactivity were determined, after centrifugation, in
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the supernatant and pellet, and used as a measurement for degraded or undegraded
ligand, respectively. The cells were washed with ice-cold PBS, membrane-associa-
ted B2036 was removed by acid wash (0.15 M NaCl, 0.05 M glycine, pH 2.2), and
internalized B2036 was determined by measuring the radioactivity after solubiliza-
tion of the acid-treated cells by 1 M NaOH. The cell extracts were counted in a LKB
gamma counter. 
Transferrin internalization
Transferrin (Tf) (Sigma) was saturated with Fe3+ and labeled with 125I (125I-Tf)
using iodo-beads (Pierce) according to standard procedures. Ts20 cells, grown in 6
well-plates, were first depleted from serum Tf by extensive washing and incubation
with 20 mM MEMα/Hepes, 4.5 g/liter glucose and 0.1% bovine serum albumin
(BSA) with or without 10 mM H2O2 for 30 min at 300C. 2µg/ml 125I-Tf was added
in each well in the absence or presence of excess unlabeled Tf (200 µg/ml), and fol-
lowed for different periods of time at 300C. The cells were first extensively washed
with MEMα/Hepes, containing 4.5 g/liter glucose and 0.1% BSA, and further
washed with ice-cold PBS. Membrane-associated Tf was removed by acid wash (20
mM MES pH 5.0, 130 mM NaCl, 50 µM desferal, 2 mM CaCl2, 0.1% BSA), fol-
lowed by a wash with MEMα/HEPES pH 7.4. Internalized Tf was determined by
measuring the radioactivity after solubilization of the acid-treated cells with
MEMα/HEPES and 0.1% BSA containing 50 µM desferal at 300C. The cell extracts
were counted in a LKB gamma counter. 
Cell lysis and western blotting
Cells, grown in dishes in presence of MEM-α supplemented with 10% FCS, peni-
cillin and streptomycin, 4.5 g/liter glucose, and 0.45 mg/ml geneticin, were treated
with 10 mM H2O2 for different periods of time at 300C. Cells were lysed on ice in
lysis buffer containing 1% Triton X-100, 1 mM EDTA, 1 mM Na3VO4, 50 mM NaF,
10 µg/ml aprotinin, 10 µg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride
in PBS. The lysates were cleared by centrifugation. GHBP appearance in the medi-
um was measured by collecting the medium of cells incubated with or without H2O2
for different periods of time. Both lysates and medium were analyzed by gel elec-
trophoresis in the presence of SDS (SDS-PAGE, 7.5% or 4-20% polyacrylamide
gradient gel) and transferred to polyvinylidene difluoride paper. The blots were
immunostained with either GHR (Mab5), anti-GHR (T), or GH antibodies. After
incubating the blots with rabbit anti-mouse IgG (RAMPO) or protein A conjugated
to HRP, antigens were visualized through the ECL system (Boehringer Mannheim).
Metabolic labeling
For metabolic labeling, the cells were incubated in methionine-free MEM for 30
min and then [35S]methionine (3.7 MBq/ml TRAN-35S labelTM, 40 TBq/mmol,
thesischap4.qxd  19-9-2001  13:51  Page 6
85
Chapter IV
ICN, Costa Mesa, CA) was added and labeled for 10 min at 300C in a CO2-incuba-
tor. The radioactivity was chased for different times with or without 10 mM H2O2
in the presence of MEMα containing 10% FCS, 4.5 g/liter glucose, and 100 µM
unlabeled methionine. The cells were further washed and lysed on ice in lysis buffer
containing 1% Triton X-100, 1 mM EDTA, 1 mM Na3VO4, 50 mM NaF, 10 µg/ml
aprotinin, 10 µg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride in PBS.
The lysates were cleared by centrifugation. Immunoprecipitations were carried out
with GHR(T) for 2 hours at 00C in 1% Triton X-100, 0.5% SDS, 0.25% sodium
deoxycholate, 0.5% bovine serum albumin (BSA), 1 mM EDTA, 1 mM Na3VO4, 50
mM NaF, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 1 mM phenylmethylsulfonyl
fluoride in PBS. Protein A-agarose beads (Repligen Co., Cambridge, MA) were
used to isolate the immuno-complexes. The immunoprecipitates were washed twice
with the same buffer and twice with 10-fold diluted PBS. The samples were boiled
in DTT and analyzed by SDS-PAGE. The radioactivity was determined using a
StormTM imaging system (Molecular Dynamics, Sunnyvale, CA) and quantified
with Molecular Dynamics Image QuaNT software version 4.2a.
GH Secretion
Ts20 cells transiently transfected with a pcDNA3-hGH construct were [35S]methio-
nine pulse-chased as described above. The radoactivity was chased for different
times, with or without 10 mM H2O2, in presence of dialysed MEMα containing
10% FCS, 4.5 g/liter glucose, and 100 µM unlabeled methionine. The medium was
collected at the time points indicated and cells lysed as described above. Both medi-
um and cleared lysates were subjected to immunoprecipitation with GH antibody,
and analyzed as above described.
Results
Oxidative stress decreases mature GHR levels independently of its UbE motif
GHR endocytosis is mediated by the ubiquitin-proteasome system, in particular,
through the UbE motif (26, 31). Upon GH stimulation, the GHR is ubiquitinated
and internalized, while in the mutated receptor (GHR-F327A), both ubiquitination
and internalization are blocked. Since the ubiquitin system plays a key role in GHR
downregulation, we asked whether GHR mature and precursor levels are affected
by oxidative stress. A time course experiment was performed in which H2O2 was
added to ts20 cell lines stably transfected with wtGHR (Fig. 1). Western blots of
lysates blotted with receptor antibodies show that, during time, the levels of mature 
forms of the receptor are decreasing, in contrast to control cells (untreated cells),
while the precursor forms are stabilized or even increased. To determine whether
the UbE motif, and, possibly, the ubiquitin conjugation system are involved, the
same experiment was performed for the cells expressing GHR-F327A. As seen in 
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Fig. 1, the GHR-F327A mutant behaved in a similar manner as the wtGHR upon
H2O2 treatment. These results suggest that the H2O2-induced downregulation is
independent of the UbE motif, and consequently of ubiquitination and endocytosis
of the GHR.
GHR internalization is inhibited upon oxidative stress, while Tf receptor inter-
nalization is unaffected
Since steady state levels of GHR are affected by oxidative stress, we investigated
whether H2O2-induced stress had an effect on regulating the amount of mature GHR
at the plasma membrane (Fig. 2). H2O2 was added to the cells and internalization of
125I-B2036, added during 6 minutes, was monitored for different periods of time,
whereafter the amounts of intracellular and degraded ligand in the medium were
determined. B2036 was used as a tag, since this ligand can bind a single receptor
and prevent dimerization, mimicking the internalization of a non-stimulated recep-
tor at the cell-surface. In both control and treated cells, the amount of cell-surface
bound 125I-B2036 decreased during time (Fig. 2A); incubation at 300C for 30 mi-
nutes resulted in uptake of about 30% of the antagonist in control cells, while only
10% was internalized in H2O2-treated cells (Fig. 2B). Thus, in cells treated with
H2O2, the amount of intracellular B2036 was markedly decreased as compared to
the control levels, and consistently, its degradation was also inhibited (Fig. 2C). The
measurement of TCA soluble radiactivity showed that for control cells, internalized
B2036 was rapidly degraded, starting after 20 minutes of chase, while in presence
of H2O2, the degradation of B2036 was almost completely inhibited. As in H2O2-
treated cells, B2036 binding sites at the plasma membrane decreased and its inter-
nalization was inhibited, we determined whether non-degradable products would
appear in the medium during time. Indeed, Fig. 2D shows that in stress conditions,
the appearance of TCA precipitable radioactivity in the medium was increased to
45% compared to 10% in control cells at 60 minutes. These results clearly show an
effect of oxidative stress on GHR downregulation.
To examine whether H2O2 affected clathrin-mediated endocytosis in general, 125I-Tf
uptake was determined in cells treated with H2O2 (Fig. 3). A short time course was
H O : - + + + + + - + + + + +
0 0.5 1 2 3 4 0 0.5 1 2 3 4
2 2
wtGHR GHR F327A
Blot: anti-GHR (T)
p
m
Fig. 1 Cellular levels of the GHR
are affected by H2O2 stress
WtGHR and GHR F327A cells were
incubated at 30°C without (control)
or with 10 mM H2O2 for the time
periods indicated. Cell lysates were
prepared and subjected to immuno-
blot analysis using anti-GHR(T).
Arrows indicate the p, precursor
GHR (110 kDa), and the m, mature
GHR (130 kDa).
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performed to measure internalization, rather than recycling. As shown in Fig. 3, 125I-
Tf internalization was only slightly affected in cells treated with H2O2, when com-
pared with control cells: only during the first 2 minutes H2O2 exerted an effect on
Tf uptake. Thus,GHR downregulation is specifically affected by oxidative stress
while endocytosis of other plasma membrane proteins is hardly affected.
GHR transport to the plasma membrane is delayed in the presence of H2O2
To further analyze the role of H2O2 on GHR regulation, we determined whether
transport from the ER to the plasma membrane plays a role in the fast decrease of
ligand binding sites at the cell-surface. A pulse-chase labeling experiment with
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Fig. 2. Internalization kinetics of wtGHR in H2O2 stress conditions. 
GH internalization was quantitated by [125I]B2036 uptake. WtGHR cells in control (open symbols)
and H2O2-treated (closed symbols) cells were incubated with 8 nM [125I] B2036 in the absence or
presence of excess unlabeled GH and chased for the indicated periods of time at 300C. A, specific cell-
surface associated [125I]B2036 and B, specific internalized [125I]B2036, were expressed as the per-
centage of total radioactivity. TCA-soluble (C) and -insoluble (D) radioactivity in the incubation medi-
um was determined and expressed as the percentage of total cell-associated and TCA-soluble label at
60 min.
%
in
te
rn
al
iz
at
io
n
0 5 10 15
0
20
40
60
80
Time (min)
Fig. 3 Transferrin internalization upon H2O2
stress treatment.
Tf internalization was quantitated by [125I]Tf
uptake. WtGHR cells in control (open symbols)
and H2O2-treated cells (closed symbols) were
incubated with 8 nM [125I]Tf in the absence or
presence of excess unlabeled Tf and chased for the
indicated periods of time at 300C. Specific inter-
nalized [125I]Tf is expressed as the percentage of
total radioactivity after short times of ligand
uptake. 
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[35S]methionine was performed, followed by an immunoprecipitation of the GHR.
As seen in Fig. 4A, the precursor form of the GHR rapidly disappeared during time,
and was converted to the mature receptor within 1 hour of chase, after which rapid
degradation occurred. When H2O2 was added, the precursor form of the GHR was
stabilized, while mature GHR only became visible after 2 hours. Quantification of
these results (Fig. 4B) indicates that in stressed cells, GHR maturation was at least
two-fold slower. To investigate whether transport to the plasma membrane was
affected by oxidative stress in general, GH secretion was monitored in a pulse-chase
labeling experiment using transiently transfected ts20 cells. As seen in Fig. 5A, after
2 hours of chase, GH was detected in the medium in both control and H2O2-treated
cells (lanes 4 and 7, respectively). Untransfected ts20 cells were used as a negative
control (lane 14). Quantification of the results of Fig. 5B shows that, in both con-
trol and H2O2-treated cells, GH was normally secreted into the medium.
Accordingly, the amount of labeled GH decreased in the cell in both situations, indi-
cating that oxidative stress plays no significant role in normal protein secretion in
these cells. 
IP: anti-GHR(T)
35S Chase: 0 10’ 30’ 1 2 3 0 10’ 30’ 1 2 3 hours
Control H O2 2
WtGHR
p
m
0 50 100 150 200
0
20
40
60
80
140
100
120
A
B
Time (min)
Fig. 4. Pulse-chase labeling with [35S] methionine of wtGHR upon H2O2 stress.
WtGHR-expressing cells were pre-incubated with methionine-free MEMα for 30 min, labeled with
[35S]methionine for 10 min at 300C and chased in the absence of radioactivity in MEMα supple-
mented with 0.1% BSA, 100 µM methionine with or without 10mM H2O2 for the indicated times. A,
cell lysates were immunoprecipitated with anti-GHR antibody (anti-GHR(T)).; p, precursor GHR (110
kDa); m, mature GHR (130 kDa). B, Radioactivity was quantified by using ImageQuant (Molecular
Dynamics) and expressed as a percentage of the radioactivity incorporated in the precursor GHR after
the pulse labeling during time. Precursor wtGHR is represented in absence of H2O2 by open symbols
and in presence of H2O2 by closed symbols. 
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Oxidative stress increases GHBP levels in the medium
Next, we addressed the question what happens to the GHR at the cell-surface in
oxidative stress, in which internalization is inhibited and, at the same time, ligand
binding sites decrease. Normally, the GHR is sensitive to proteolytic cleavage at the 
cell-surface, in particular by a metalloprotease called tumor necrosis factor (TNF)-
α-converting enzyme (TACE or ADAM-17) (32), which generates a soluble circu-
lating form of the receptor in the medium/blood. This process, also known as shed-
ding, leads to the appearance of GH binding protein (GHBP) which is identical to
the extracellular domain of the GHR and competes with the receptor for ligand-
binding (33). To determine whether this process is affected in stressed cells, the
appearance of GHBP in the medium was determined during time in wtGHR-trans-
fected cells treated with H2O2 (Fig. 6A). Samples from the medium were collected
at different times and analyzed by western blot with an antibody recognizing the
extracellular domain of the GHR/GHBP. As seen in Fig. 6A for the wtGHR, H2O2
medium lysate
H O :2 2 - - - - + + + - - - + + + +
1 2 3 4 5 6 7 8 9 10 11 12 13 14
IP: anti-GH
35S: 2 0 1 2 0 1 2 0 1 2 0 1 2 2
0 1 20
20
40
60
80
100
120
A
B
ts20
Fig. 5 Pulse-chase labeling with [35S]methionine of GH sorting upon H2O2 stress.
GH-transiently transfected ts20 cells were pre-incubated with methionine-free MEMα for 30 min,
labeled with [35S]methionine for 10 min at 300C and chased in MEMα supplemented with 0.1% BSA,
100 µM methionine and with or without 10mM H2O2 for the indicated times. A, cell lysates were
immunoprecipitated with anti-GH antibody (anti-GH). Untransfected ts20 cells were used as a nega-
tive control (lane 14); B, radioactivity was quantified by using ImageQuant (Molecular Dynamics) and
expressed as the percentage of total radioactivity in both the cell and medium for each time point. GH
appearance in the medium is represented in absence of H2O2 by open squares and in presence of H2O2
by closed squares. GH disappearance in the cells is represented in absence of H2O2 by open triangles
and in presence of H2O2 by closed triangles.
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incubation lead to an increase of GHBP in the medium, when compared to untrea-
ted cells. In particular, after 2 hours, a difference between control and H2O2-treated
cells is evident. Fig. 6B demonstrates that the appearance of GHBP in the medium
during time is not due to an increased amount of cells in the experiment. To further
determine the role of the UbE motif in this process, the same experiment was per-
formed for the GHR-F327A cells. As seen in Fig. 6C, GHBP appearance in the
medium was increased in H2O2-treated cells just as for the wtGHR cells, with sim-
ilar amounts of receptor for each lane, reflecting again that the increased shedding
is independent of the UbE motif. These results indicate that shedding is increased
in stressed cells and it explains why less intact receptors are found at the cell-sur-
face and, as shown in Fig. 2A, the amount of ligand binding sites are decreased dur-
ing time.
Discussion
The ubiquitin-proteasome system is known to play a role in selective degradation
of cytosolic and nuclear proteins (34) and to be involved in the degradation of mis-
folded endoplasmic reticulum proteins (35). Stress, viral infection, oxidative and
chemical damage trigger vital cellular response, in particular by activating the ubi-
quitin-proteasome system, either to repair the damage, or to limit its toxicity to the
cell. In response to several types of stress, organisms ranging from bacteria to
humans induce several highly conserved gene families called heat shock proteins
(Hsps). In yeast, the C-type cyclin Ume3p, part of a complex necessary for repres-
sion of genes of the Hsp70 family, is rapidly degraded by the ubiquitin-proteasome
system in cells subjected to heat shock (36), suggesting that degradation of this pro-
Fig. 6. Effect of H2O2 on the shed-
ding of the GHR.
Cells expressing wtGHR and GHR-
F327A were incubated without or
with H2O2 for different periods of
time at 300C. After each time point,
the medium was collected and ana-
lyzed by Western blotting using an
anti-GHR (Mab5) (A). As a control,
the cells were lysed and subjected to
the same procedure (B). 
4 0 1 2 4 0 1 2 4 hours
Blot: anti-GHR (Mab5)
control H O2 2
4 0 1 2 4 0 1 2 4 hours
control H O2 2
Blot: anti-GHR (Mab5)
0 4 4 0 2 4 0 2 4 hours
ts20 wtGHR (medium)
ts20 wtGHR (lysate)
lysate medium
H O : - - + - - - + + +2 2
GHR F327A
Blot: anti-GHR (Mab5)
A
B
C
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tein is part of the cellular response to stress. In mammalian cells, the p53 tumor sup-
pressor protein, which is normally degraded through the proteasome following
interaction with the ubiquitin ligase Mdm2 (37, 38), becomes activated by diverse
stress signals, resulting in stabilization and accumulation of p53 (39). In this way,
p53 can function to inhibit tumor growth by activating target genes that mediate
both cell cycle arrest and apoptosis in stressed cells.
In this study, we addressed the role of oxidative stress in modulating GHR levels in
the cell and its effect on receptor availability. The GHR is normally downregulated
by the ubiquitin-proteasome system upon ligand binding, and depends on ubiquitin
conjugation for its endocytosis (26). The GHR, when at the cell-surface and in
absence of ligand, is subjected to shedding, a process that requires the enzyme
TACE, releasing GHBP due to the cleavage of the extracellular domain of the
receptor (32). Upon ligand binding, the extracellular domain is protected from shed-
ding (cleavage), and the GHR becomes ubiquitinated in clathrin coated pits (40),
triggering clathrin-dependent endocytosis. Upon stress, the ubiquitin system is trig-
gered to activate or downregulate specific proteins in the cell, and possibly also the
GHR. Herein, we present evidence that in oxidative stress, the number of GHRs at
the cell-surface is significantly reduced. H2O2 treatment induces a decrease in
mature levels of the GHR in ts20 cells (Fig. 1), partially due to a delay in receptor
maturation (Fig. 4). A delay of 30 minutes occurs in the maturation of the GHRs in
the cell upon oxidative stress, and inhibition of the transport from the ER to Golgi
leads to approximately 50% less receptors at the cell-surface at its steady state level
(Fig.1). This stress-induced effect is specific for the GHR, as other secretory pro-
teins, like GH itself, are not affected in their transport to the plasma membrane (Fig.
5). These results partially explain the decrease of mature GHR levels at the cell-sur-
face. Furthermore, both wtGHR and the internalization mutant GHR-F327A show
the same effect on protein turnover, suggesting that the UbE motif plays no signif-
icant role in the delayed transport to the cell-surface. This does not exclude the pos-
sibility that the downregulation of the GHR is controlled by the ubiquitin system,
as another region/motif could be involved or even a protein attached to the recep-
tor's tail could be somehow regulated by the ubiquitin system. By testing the effect
of oxidative stress on the receptor levels at the plasma membrane, we observed that
the ligand-binding sites at the cell-surface decrease faster in H2O2-treated cells than
in control cells (Fig. 2A and results using GH, not shown). However, the decrease
of GHR at the cell-surface was not due to a faster internalization from the cell-sur-
face, as assayed by the GH-antagonist B2036 (Fig. 2B). Instead, the receptor
remained longer at the cell-surface than in control cells, indicating that, other fac-
tor(s) are contributing to this downregulation of the GHR upon oxidative stress.
This stress-induced inhibition is specific, as it is not observed in other plasma mem-
brane proteins, like for instance, the Tf receptor which internalizes normally in
H2O2-treated cells (Fig. 3). Furthermore, TCA-soluble products appear in the medi-
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um in control cells after 20 minutes of B2036 uptake, while in H2O2-treated cells,
the appearance of such products is significantly decreased (Fig. 2C). In contrast,
TCA-insoluble products are increased several-fold in stressed cells (Fig. 2D), indi-
cating that the decrease of ligand-binding sites at the cell-surface was due to the
action of a protease that cuts the receptor from the extracellular domain. Indeed, an
enhancement of the shedding activity in the GHR was observed in stressed cells
(Fig. 6). TACE catalyzes the shedding of GHR from its extracellular domain and
can be induced by phorbol ester stimulation (41). Possibly, TACE-mediated GHR
proteolysis might be regulated by both oxidative stress and the ubiquitin system
pathways, explaining the appearance of higher levels of GHBP in the medium.
Alternatively, as oxidative stress induces an inhibition of receptor downregulation
from the cell-surface, more receptors at the cell-surface are available for shedding,
inducing therefore an increase of GHBP levels. This is unlikely because shedding
of the endocytosis-mutant receptor GHR-F327A is increased in oxidative stress
conditions.
These findings demonstrate for the first time that the availability of the GHR might
be regulated by the oxidative-stress response pathway, and that GHR levels at the
cell-surface are significantly reduced in response to oxidative stress. H2O2 acts at
three stages: it delays maturation and/or transport of the GHR to the cell-surface, it
inhibits GHR endocytosis from the cell-surface, and it increases shedding activity.
These combined factors lead to an efficient decrease in GHR's availability in the
cell and, in this way, diminish the capacity of the GHR to stimulate protein synthe-
sis and cellular growth, in order to give the cell the chance to first recover from the
oxidative stress.
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The signal transduction of the GHR is regulated by the ubiq-
uitin-proteasome system
The results presented in chapter 2 indicate that GH-induced tyrosine phosphoryla-
tion of the GHR and JAK2 are prolonged in presence of proteasomal inhibitors,
suggesting a role of the ubiquitin-proteasome system in signal regulation. In seve-
ral cytokine receptors the JAK/STAT pathway is known to be downregulated by the
proteasome. Upon treatment with specific proteasomal inhibitors, both interleukin-
2 and -3 and interferon-γ receptor showed a prolonged JAK/STAT activation as well
as other signaling molecules like the MAP kinases (1, 2). Furthermore, endocytosis
plays no significant role in this proteasome-dependent downregulation of both
JAK2 and GHR activities. Since signaling by the GHR-F327A endocytosis-defi-
cient mutant still depends on the proteasome for its downregulation, our data indi-
cate that proteasomal action on signal transduction occurs at the cell-surface .
Phosphatases or SOCS?
Our results with GHR 1-399 and GHR 1-369 indicate that partial deletion of the C-
terminal GHR tail leads to a prolonged JAK2 phosphorylation presumably due to
loss of a negative regulator binding site and its consequent activation. Tyrosine
phosphatases, SHP-1 and SHP-2, and SOCS proteins, CIS and SOCS3, are involved
in the dephosphorylation/inactivation of JAK proteins and subsequent termination
of GH-induced cellular growth (3- 6). Upon ligand binding, SHP-2 and the various
SOCS are known to interact with the region proximal to the C-terminal cytosolic
tail of the GHR or with JAK2 itself. One explanation might be that the phosphatase
activity is modulated by proteasome function, perhaps by degrading an inhibiting
complex in a similar manner as it occurs for the inhibitor of the transcription factor
NF-κB (7). In support of this model, SHP-1 degradation has been shown to be ubi-
quitin-dependent in mast cells (8), suggesting that the proteasome is involved in
SHP-1 regulation. However, SHP-1 does not directly interact with the cytosolic tail
of the GHR, rendering our results difficult to interpret. SHP-2, however, has been
shown to interact directly with the tail of the GHR (residues 484-620) and to asso-
ciate with JAK2 via SIRPα1 (9). SIRPα1 acts as a negative regulator of GH sig-
naling by its ability to bind SHP-2 (9), and the proteasome could therefore play a
role in SHP-2/SIRPα1 association and binding to JAK2. As SHP-2 is known to
associate to other signaling molecules as IRS-1 (10) and p85-PI-3K (11), future
studies will indicate whether the MG132 effect on these molecules is directly rela-
ted to SHP-2 activity. Another explanation for our results comes from the action of
the negative regulators of GHR signaling, the SOCS proteins. It is assumable that
activated JAK kinases themselves are subject to proteasome-mediated degradation,
possibly through the action of SOCS. Support for this comes from the recent iden-
tified and highly conserved C-terminal homology domain of the SOCS proteins,
termed the SOCS box, which mediates interactions with elongins B and C, which
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in turn may couple SOCS proteins and their substrates to the proteasomal protein
degradation pathway (12). SOCS-3 binds to the GHR close to the transmembrane
domain and might inhibit JAK2 signaling by interfering with JAK2 binding to the
box-1 region; SOCS-1 acts at the level of JAK2 tyrosine kinase, as JAK2 tyrosine
phosphorylation is strongly inhibited by SOCS-1 protein (13) and, in addition,
interacts with the C-terminal residues of GHR, which may serve to correctly orien-
tate SOCS-1 or perhaps increase its affinity for the receptor-kinase signaling com-
plex (13); SOCS-2 and CIS, although to a lesser extent than SOCS-3 and with dif-
ferent kinetics (13), bind the C-terminal cytoplasmic domain of the GHR and, in
particular, the docking sites for STAT5 (14). The inhibition by CIS or SOCS-2 of
GHR-JAK2 signaling to STAT5 could result from direct competition between
STAT5 and either CIS or SOCS-2 for tyrosine-phosphorylated binding sites on
GHR. Alternatively, the inhibition of GH signaling by CIS or SOCS-2 could involve
SOCS/CIS protein ubiquitination followed by degradation of the  SOCS/CIS-bound
GHR-JAK2 complex. How SOCS proteins inhibit JAK kinase activity is still not
clear, but analogous to the family of F-box-containing proteins, SOCS box interac-
tion with elongins B and C potentiates interaction with the proteasome complex.
Interestingly, elongin B contains an ubiquitin-like (UBL) sequence at its N-termi-
nus (15), suggesting a model for the action of the SOCS proteins (See Fig. 3,
Chapter 1). This model suggests that either through direct interactions of the elon-
gin B UBL domain with the proteasome or through associated Cullin-2-induced
ubiquitination of substrates and subsequent proteasomal association, JAK2 and the
associated SOCS proteins may be destroyed (12). This would explain why, in pres-
ence of MG132, degradation of SOCS proteins and its associated proteins like
JAK2 would be prevented, and therefore induce sustained activation of JAK2 and,
consequently of the GHR. 
In favor of this model, is the finding that CIS and SOCS-1 are degraded in a pro-
teasome-dependent manner (12, 16), and that SOCS-1 was shown to program VAV
for ubiquitin-proteasome-mediated degradation by acting as a substrate-specific
recognition component of a VCB-like ubiquitin ligase complex (16). Furthermore,
CIS became ubiquitinated and its degradation was inhibited in presence of protea-
some inhibitors upon EPOR stimulation (17). CIS was further shown to inhibit
GHR-JAK2 signaling by two distinct mechanisms: (i) a partial inhibition that is
decreased at elevated STAT5b levels and may involve competition between CIS and
STAT5b for common GHR cytoplasmic tail phosphotyrosine-binding sites, (ii) and
by a time-dependent inhibition, not seen with SOCS-3, that involves proteasome
action (18). GH was shown to induce degradation of CIS, but not SOCS-3, and the
proteasome inhibitor MG132 blocked CIS degradation as well as its inhibitory
action on STAT5b signaling (18). Proteasome-dependent degradation of CIS, most
likely in a (GHR-JAK2)-CIS complex, is therefore proposed to be an important step
in the time-dependent CIS inhibition mechanism. Recently, it was demonstrated
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that suppression of JAK2 activity was dependent on SOCS-1, where the SOCS box
was suggested to mediate proteasomal degradation of JAK2 rather than JAK2
kinase inhibition (19). The SOCS box of SOCS-1 was found to interact with the E3
Cullin-2 and promoted ubiquitination of JAK2. This interaction demonstrated the
substrate-specific E3 ubiquitin-ligase-like activity of SOCS-1 for activated JAK2,
providing a novel strategy for the suppression of oncogenic tyrosine kinases (19).
Thus, the mechanisms for the termination of the GHR phosphorylation might
depend on proteolysis: the regulation of both the phosphatases and the SOCS pro-
teins activity. Further studies will be necessary to determine which of these groups
of proteins, or a combination of both, is indeed involved in proteasome-dependent
signal downregulation.
Signaling of the GHR continues in endosomes
Our data show that initiation as well as termination of both JAK2 and GHR phos-
phorylation can occur at the cell-surface. The observation that JAK2 phosphoryla-
tion was prolonged in the truncated forms of the GHR raised the question of what
happens to the signal transduction of the GHR after its internalization. If the GHR
is partially truncated by the proteasome during internalization, a truncated form
might have a higher signaling capacity than the full-length GHR, once it has lost the
binding sites for SHPs or SOCS. This implicates that JAK2 might still be active in
endosomes. Co-immunoprecipitation of GH-GHR complexes containing either
wtGHR or GHR 1-369 truncated form, before and after endocytosis showed that
JAK2 as well as other activated proteins are bound to the GHR not only at the cell-
surface but also intracellularly, suggesting that the GHR signal transduction conti-
nues in endosomes. This is not unexpected because GH keeps the two GHRs com-
plexed after endocytosis. In this configuration, JAK2 has high affinity for the com-
plex and will either rebind (if it was removed during passage of the coated pits) or
will keep its position on the dimerized tails once internalized. The relevance for sig-
nal transduction in endosomes is not clear. It is possible that the signaling GHR-
complexes in endosomes differ from those at the cell-surface. However, our results
indicate that phosphorylated proteins in total and endocytosed GH complexes in
wtGHR and GHR 1-369 look very similar, suggesting that GHR signal transduction
continues or resumes after endocytosis.
Additionally, these results provide evidence that GHR is present in endosomes both
in its full-length and truncated form, suggesting that the receptor might be partially
downregulated by the proteasome. The GHR is C-terminally truncated already at
the cell-surface as the GHR-F327A presented similar truncated forms.The trunca-
ted GHR can endocytose, complexed to GH, and even in presence of proteasome
inhibitors its formation can still occur. It remains to be determined, whether this
truncated GHR plays a role in signal transduction. Data from GHR truncated forms
did present prolonged JAK2 phosphorylation during time, suggesting that such a
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truncated receptor could also have an increased capacity of signaling.
Internalization and ubiquitination of the GHR are independ-
ent of GHR signal transduction via JAK2
In this study, as discussed in chapter 3, we examined the role of JAK2-mediated
signal transduction in GHR internalization and downregulation. JAK2 is essential
for the signaling of the GHR, as it is the first step in the activation of several cas-
cades that lead to the biological responses of the GHR. Mutation of the attachment
site for JAK2, box-1, in the GHR cytoplasmic tail resulted in the abrogation of
JAK2 association with the GHR cytoplasmic domain, and in the complete absence
of GHR and JAK2 phosphorylation. Although mutation of the box-1 region in the
GHR did not affect the ability of the altered receptor to bind GH at the cell surface,
it dramatically affected the receptor's capacity to couple GH binding to JAK2 acti-
vation and consequently of other possible signaling molecules. A previous report
suggested that mutations in box-1 may lead to a block of GHR endocytosis (20). In
our study, the same modification did not alter the rate and extent of receptor-bound
GH internalization as compared to a functional GHR, nor did it change its matura-
tion and transport to the plasma membrane. GH is still normally targeted for degra-
dation in GHR4P-A, indicating that intracellular sorting and transport to the lysosome
is not affected in box-1-defective receptors. However, upon GH stimulation,
wtGHR mature form showed relatively faster degradation, while addition of GH
had no such clear effect on the turnover of the GHR4P-A. This suggests that GH-
dependent wtGHR accelerated degradation is mediated through a JAK2-dependent
process that is absent in GHR4P-A, indicating that signal transduction is contributing
to a faster endocytosis/degradation of the GHR. This might be due to the fact that
the signal transduction pathway via STAT or MAP kinase stimulates the clathrin-
mediated endocytosis, a phenomenon known from the EGF receptor studies (21). 
In addition, both wtGHR and mutated receptor were still normally ubiquitinated and
remained dependent on both an intact ubiquitin system and on proteasomal action
for its GH-dependent internalization. Thus, GHR/JAK2 signal transduction plays
no role in the binding of the E2/E3 enzymes, members of the ubiquitin conjugation
system, to the receptor. Furthermore, the motif at the GHR tail responsible for the
proteasome action (22) does not interact with signaling proteins nor is such an inte-
raction or phosphorylation itself important for the proteasome action. Together,
these results demonstrate that the molecular mechanism which underlies the ubi-
quitin-proteasome system-dependent endocytosis of the GHR does not require the
presence nor the activity of JAK2 and its signaling molecules.
Thus, the ubiquitin-proteasome system independently regulates the signal transduc-
tion capacity of the GHR in two ways: first, it determines the rate of endocytosis via
the UbE-motif in the GHR tail, and second, it determines the signaling time via
JAK2 and SOCS. Both mechanisms appear to be independently regulated by the
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same system, probably via completely different E2/E3 enzyme systems. 
In addition to the dispensability of JAK2 activity and receptor tyrosine phosphory-
lation, recruitment of Grb2 to bind the receptor via SHC and consequent activation
of the MAPK pathway is also not required for GHR downregulation (23). Cells
expressing truncated receptors that lack this domain and are therefore unable to
associate with Grb2, can internalize the truncated receptor as efficiently as cells
containing wtGHR. Similarly, Src, known to be essential for phosphorylation of
clathrin and consequent EGF receptor endocytosis (24), does not play any role in
GHR clathrin-dependent endocytosis. Furthermore, it has recently been published
that neither activation of another member of the cytokine family, the erythropoietin
receptor, nor JAK2 tyrosine kinase activity are required for internalization of bound
erythropoietin (25). Taken together, these results suggest that, for signaling recep-
tors of the cytokine receptor superfamily, endocytosis follows a pathway distinct
from signaling receptors of the RTK family.
Thus, GHR ubiquitination, endocytosis and degradation occur independently of
GHR signal transduction via JAK2. We conclude that, while endocytosis and degra-
dation require the ubiquitin system, they are independent of GHR signal transduc-
tion.
GHR availability at the plasma membrane is regulated by
oxidative stress
In Chapter 4, we address the role of oxidative stress in modulating GHR levels in
the cell and its affect on receptor availability. Oxidative stress activates the ubiqui-
tin-proteasome system, and induces higher levels of ubiquitin-protein conjugates in
the cells with concomitant lower free ubiquitin levels (26-29), triggering the acti-
vation or downregulation of specific proteins in the cell, and possibly also the GHR.
Our data indicate that an immediate effect of oxidative stress, is a higher turnover
rate of the GHR, and as a consequence the GHR levels are significantly reduced
from the cell-surface. H2O2-induced decrease of GHR levels at the cell-surface is
accomplished by: (i) delaying its transport to the plasma membrane, (ii) inhibiting
its internalization and (iii) enhancing shedding activity. This stress-induced inhibi-
tion is quite specific, as it is not observed for other plasma membrane proteins, like
the Tf receptor that can still internalize in H2O2-treated cells. In addition, this effect
is independent of the UbE motif of the GHR, as, upon stress, the GHR-F327A
behaves in a similar manner as the wtGHR. This does not exclude the possibility
that the downregulation of the GHR is being controlled by the ubiquitin system, as
another region of the receptor could be involved or even a protein attached to the
receptor's tail could be somehow regulated by the ubiquitin system. The partial inhi-
bition of GHR’s transport to the cell-surface in H2O2-treated cells is specific for the
GHR, as other secretory proteins, like GH itself, are not affected in their transport
to the plasma membrane. The enhancement of the shedding activity in the GHR is
Summarizing discussion
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observed in stressed cells, and is probably due to the fact that TACE-mediated GHR
proteolysis is up-regulated by both oxidative stress and the ubiquitin system path-
ways. Alternatively, as oxidative stress induces an inhibition of receptor downre-
gulation from the cell-surface, more receptors at the cell-surface are available for
shedding, inducing an increase of GHBP levels. Whether the two mechanisms are
connected, is still unclear.
These findings demonstrate, for the first time, that the availability of the GHR might
be regulated by the oxidative-stress response pathway, and, in this manner, dimi-
nish possible GHR biological effects, like protein synthesis and cellular growth, in
order to give the cell the chance to first recover from oxidative stress.
“It is better to be approximately right 
than to be precisely wrong”.
Maynard Keynes 
Chapter V
thesischap5.qxd  19-9-2001  14:00  Page 7
102
References:
1. Yu, C. L., and Burakoff, S. J. (1997) J. Biol. Chem. 272, 14017-20
2. Callus, B. A., and Mathey-Prevot, B. (1998) Blood 91, 3182-3192
3. Adams, T. E., Hansen, J. A., Starr, R., Nicola, N. A., Hilton, D. J., and
Billestrup, N. (1998) J. Biol. Chem. 273, 1285-1287
4. Klingmuller, U., Lorenz, U., Cantley, L. C., Neel, B. G., and Lodish, H. F. (1995)
Cell 80, 729-738
5. Hackett, R. H., Wang, Y. D., Sweitzer, S., Feldman, G., Wood, W. I., and Larner,
A. C. (1997) J. Biol. Chem. 272, 111280-11132
6. Jiao, H., Berrada, K., Yang, W., Tabrizi, M., Platanias, L. C., and Yi, T. (1996)
Mol. Cell. Biol. 16, 6985-6992
7. Yaron, A., Gonen, H., Alkalay, I., Hatzubai, A., Jung, S., Beyth, S., Mercurio, F.,
Manning, A. M., Ciechanover, A., and Ben-Neriah, Y. (1997) EMBO J. 16, 6486-
6494
8. Piao, X., Paulson, R., van der Geer, P., Pawson, T., and Bernstein, A. (1996) Proc.
Natl. Acad. Sci. U. S. A. 93, 14665-14669
9. Stofega, M. R., Argetsinger, L. S., Wang, H., Ullrich, A., and Carter-Su, C.
(2000) J. Biol. Chem.,
10. Myers, J., M. G., Mendez, R., Shi, P., Pierce, J. H., Rhoads, R., and White, M.
F. (1998) J. Biol. Chem. 273, 26908-26914
11. Gesbert, F., Guenzi, C., and Bertoglio, J. (1998) J. Biol. Chem. 273, 18273-
18281
12. Zhang, J. G., Farley, A., Nicholson, S. E., Willson, T. A., Zugaro, L. M.,
Simpson, R. J., Moritz, R. L., Cary, D., Richardson, R., Hausmann, G., Kile, B.   
J., Kent, S. B. H., Alexander, W. S., Metcalf, D., Hilton, D. J., Nicola, N. A., and
Baca, M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 2071-2076
13. Ram, P. A., and Waxman, D. J. (1999) J. Biol. Chem. 274, 35553-25561
14. Hansen, J. A., Hansen, L. H., Wang, X., Kopchick, J. J., Gouilleux, F., Groner, 
B., Nielsen, J. H., Moldrup, A., Galsgaard, E. D., and Billestrup, N. (1997) J.
Mol. Endocrinol. 18, 213-221
15. Lonergan, K. M., Iliopoulos, O., Ohh, M., Kamura, T., Conaway, R. C.,
Conaway, J. W., and Kaelin, W. G., Jr. (1998) Mol. Cell. Biol. 18, 732-741
16. De Sepulveda, P., Ilangumaran, S., and Rottapel, R. (2000) J. Biol. Chem. 275,
14005-14008
17. Verdier, F., Chretien, S., Muller, O., Varlet, P., Yoshimura, A., Gisselbrecht, S.,
Lacombe, C., and Mayeux, P. (1998) J. Biol. Chem. 273, 28185-28190
18. Ram, P. A., and Waxman, D. J. (2000) J. Biol. Chem. 275, 39487-39496
19. Kamizono, S., Hanada, T., Yasukawa, H., Minoguchi, S., Kato, R., Minoguchi, 
M., Hattori, K., Morita, S., Kitamura, T., Kato, H., Nakayama Ki, K., and
Yoshimura, A. (2001) J. Biol. Chem. Papers in Press
Summarizing discussion
thesischap5.qxd  19-9-2001  14:00  Page 8
103
Chapter V
20. Allevato, G., Billestrup, N., Goujon, L., Galsgaard, E. D., Norstedt, G., Postel-
Vinay, M. C., Kelly, P. A., and Nielsen, J. H. (1995) J. Biol. Chem. 270, 17210-
17214
21. Sorkin, A., Mazzotti, M., Sorkina, T., Scotto, L., and Beguinot, L. (1996) J.
Biol. Chem. 271, 13377-13384
22. van Kerkhof, P., Govers, G., Alves dos Santos, C. M., and Strous, G. J. (2000)
J. Biol. Chem. 275, 1575-1580
23. Vanderkuur, J. A., Butch, E. R., Waters, S. B., Pessin, J. E., Guan, K. L., and
Carter-Su, C. (1997) Endocrinol. 138, 4301-4307
24. Wilde, A., Beattie, E. C., Lem, L., Riethof, D. A., Liu, S.-H., Mobley, W. C.,
Soriano, P., and Brodsky, F. M. (1999) Cell 96, 677-687
25. Beckman, D., Lin, L. L., Quinones, M. E., and Longmore, G. D. (1999) Blood
94, 2667-2675
26. Finley, D., Ozkaynak, E., and Varshavsky, A. (1987) Cell 48, 1035-1046
27. Kulka, R. G., Raboy, B., Schuster, R., Parag, H. A., Diamond, G., Ciechanover,
A., and Marcus, M. (1988) J. Biol. Chem. 263, 15726-15731
28. Carlson, N., and Rechsteiner, M. (1987) J. Cell Biol. 104, 547-555
29. Shang, F., Gong, X., and Taylor, A. (1997) J. Biol. Chem. 272, 23086-23093
thesischap5.qxd  19-9-2001  14:00  Page 9
